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Abstract  34 
JC polyoma virus (JCV) infection is highly prevalent and usually kept in a persistent 35 
state without clinical signs and symptoms. Only during immunocompromise and 36 
especially impaired CD4+ T cell function in the brain, as seen in AIDS patients or 37 
natalizumab-treated multiple sclerosis patients, JCV may cause progressive multifocal 38 
leukoencephalopathy (PML), an often life-threatening brain disease.  39 
Since CD4+ T cells likely play an important role in controlling JCV infection, we here 40 
describe the T cell response against JCV in a group of predominantly HLA-DR-41 
heterozygotic healthy donors (HD) by using a series of overlapping 15-mer peptides 42 
spanning all JCV-encoded open reading frames. We identified immunodominant 43 
epitopes and compared T cell responses with anti-JCV VP1 antibody production and 44 
with the presence of urinary viral shedding.  45 
We observed positive JCV-specific T cell responses in 28.6-77.6%, humoral immune 46 
response in 42.6-89.4% and urinary viral shedding in 36.4-45.5% of HD depending on 47 
the threshold. Four immunodominant peptides were mapped, and at least one 48 
immunogenic peptide per HLA-DRB1 allele was detected in DRB1*01+, DRB1*07+, 49 
DRB1*11+, DRB1*13+, DRB1*15+, and DRB1*03+ individuals. We show for the first time, 50 
that JCV-specific T cell responses may be directed not only against JCV VP1 and Large 51 
T antigen, but also against all other JCV-encoded proteins. Heterozygotic DRB1*04:01+ 52 
individuals showed very low T cell responses to JCV together with normal anti-VP1 53 
antibody levels and no urinary viral shedding, indicating a dominant-negative effect of 54 
this allele on global JCV-directed T cell responses. Our data are potentially relevant for 55 
the development of vaccines against JCV. 56 
  57 
 58 
 59 
60 
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Introduction 61 
 JC virus (JCV) is a member of the polyomaviridae (PyVs) family (48), a small, 62 
DNA virus family, which encompasses eight more human viruses: BK PyV (BKV) (19), 63 
KI PyV (KIV) (2), WU PyV (WUV) (21), Merkel cell PyV (MCV) (17), HPyV6 and HPyV7 64 
(51), trichodysplasia spinulosa-associated PyV (TSV) (62) and HPyV9 (52). JCV 65 
consists of a circular double-stranded DNA genome of 5130bp length and three capsid 66 
proteins, namely VP1, VP2 and VP3, with the major capsid protein VP1 being able to 67 
self-assemble into virus-like-particles (47), and a few additional proteins, agnoprotein, 68 
large T (LT) antigen, small T (ST) antigen and three T’ antigens (T’135, T’136 and 69 
T’165) (18).  70 
Infection with JCV is common in healthy individuals with IgG seroprevalence rates 71 
between 58% and 84% (15, 66). JCV entry into the organism might occur via infection 72 
of tonsillar tissue after inhalation or via fecal-oral route, but also by vertical transmission 73 
(6, 41). Usually, JCV infection remains clinically unapparent, and the virus persists in 74 
tonsils and hematopoietic precursor cells in the bone marrow. In a large fraction of 75 
infected individuals JCV also infects kidney epithelial cells and is associated with viral 76 
shedding in the urine in approximately 50% of individuals (35). The reasons for urinary 77 
viral shedding in only a fraction of infected individuals are not clear. Under 78 
circumstances of immunocompromise and especially impaired CD4+ T cell function 79 
such as late-stage HIV infection, hematological malignancies, organ transplantation, but 80 
also in clinically inconspicuous idiopathic CD4+ lymphopenia, JCV is able to cause an 81 
opportunistic infection of the brain, PML (35, 58). PML is caused by infection of 82 
oligodendrocytes and astrocytes by neurotropic JCV strains with altered regulatory 83 
regions and often certain amino acid exchanges in the JCV major capsid protein VP1 84 
when compared to archetypic strains (24, 27). Cell lysis of oligodendrocytes leads to 85 
widespread demyelination, serious neurological impairment with fatal outcome in 30 to 86 
50% of cases (35, 58). Besides the abovementioned causes, PML has become a 87 
serious concern during therapy with a few monoclonal antibodies, e.g. MS patients 88 
receiving the highly effective and usually well-tolerated antibody against α-4-integrin 89 
(VLA-4; CD49d), natalizumab, but also in systemic lupus erythematosus and psoriasis 90 
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patients receiving anti-CD20 and anti-LFA-1 antibodies respectively (35, 58). Until now 91 
285 out of 104,400 natalizumab-treated MS patients have developed PML in the post-92 
marketing setting worldwide, and approximately 22% have died from the complication 93 
(61). Current risk estimates vary between 2.33:1000 and 2.95:1000 in MS patients on 94 
natalizumab therapy, but rise to approximately to 9:1000 or higher in JCV seropositive 95 
individuals with more than 2 years treatment and prior immunosuppression (61). The 96 
treatment complication of PML therefore threatens to lead to serious regulatory 97 
restrictions or even market withdrawal.  98 
 JCV-specific immunity is probably not only important for containing JCV infection 99 
in healthy individuals, but also for recovery from PML, since immune reconstitution is 100 
associated with the best clinical outcome among patients with PML (8, 13, 37). Serum 101 
antibodies against JCV are frequent in clinically healthy individuals, whereas intrathecal 102 
JCV-specific antibodies are found at high prevalence and high titers in PML patients 103 
(66). Furthermore, JCV-specific IgG increases during PML disease course of PML 104 
survivors (30). However, as most PML patients harbour JCV-specific antibodies before 105 
or at onset of the disease (5), the humoral immune response may not be sufficient to 106 
prevent the development of PML. JCV-specific, cellular immune responses have been 107 
investigated as well, particularly the role of CD8+ cytotoxic T cells (12, 31). In individuals 108 
expressing the common human leukocyte antigen (HLA) class I molecule, (HLA-) 109 
A*02:01, two nonamer peptides have been identified as immunodominant JCV peptides: 110 
VP1 (100-109) peptide (ILMWEAVTL) and VP1 (36-44) peptide (SITEVECFL) (12, 31). 111 
The frequency of CD8+ T cells specific for these epitopes varies between 1:100,000 to 112 
1:2,494 in peripheral blood mononuclear cells (PBMC), and 73% of immunocompetent 113 
individuals possess such cells (14). JCV-specific CD8+ T cells have been shown in 91% 114 
of PML survivors, while they are only detectable in 9% of PML progressors (31). 115 
Furthermore, the number of JCV-specific CD8+ T cells at the onset of the disease can 116 
predict subsequent disease progression. Based on these data it has been concluded 117 
that the JCV-specific CD8+ cytotoxic T cell response is essential for the prevention of 118 
and resolution from PML. 119 
 Despite the forecited experience of an increased risk of PML in AIDS patients 120 
with low CD4+ T levels, and in patients with idiopathic CD4+ lymphocytopenia, both 121 
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suggesting an important role of JCV-specific CD4+ T cells in the control of JCV infection, 122 
CD4+ T cell function has been examined in fewer studies. Peripheral CD4+ T cell counts 123 
below 200 cells/µl at the time of PML diagnosis were found associated with progression 124 
and lower survival rate at one year compared to CD4+ T cell counts above 200 cells/µl 125 
(37). CD4+ T cells reactive to JCV-like particles have been detected in healthy and HIV-126 
infected non-PML individuals with urinary excretion of JCV (20). Furthermore, HIV-127 
infected PML survivors harbour CD4+ T cells reactive to JCV-like particles, while they 128 
are absent in HIV-infected individuals with active PML (20). With 80% of PML patients 129 
suffering from AIDS as underlying disease, and reciprocally up to 5% of AIDS patients 130 
developing PML (35, 58), CD4+ T cells are likely of particular importance in the control 131 
of JCV. Moreover, like antibody-producing B cells, CD8+ T cells are at least in part 132 
dependent on functional help by CD4+ T cells. Supporting this notion we have recently 133 
demonstrated that JCV-specific CD4+ T cells of T helper 1 (Th1) or Th1-2 phenotypes 134 
predominantly infiltrate the brain in PML-immune reconstitution inflammatory syndrome 135 
(PML-IRIS), a condition occurring for example upon washout of natalizumab in MS or 136 
restoration of CD4+ numbers in AIDS patients (3). While PML-IRIS and the 137 
accompanying inflammation and swelling of the brain are also life-threatening, it leads 138 
to the elimination of JCV infection and PML and underscores the role of CD4+ T cell 139 
responses. 140 
In the present study we used a series of overlapping peptides that span all six open 141 
reading frames of JCV including the 35 most frequent variants of JCV and characterized 142 
the proliferative response in 49 healthy donors (HD). We subsequently identified 143 
immunodominant epitopes out of the four most immunogenic pools. As expected and 144 
consistent with the fact that our strategy primarily tested CD4+ T cells we found that the 145 
responses depend on the HLA-class II haplotype with respect to peptide specificity and 146 
magnitude of the response. Of particular note, HLA-DRB1*04:01+ donors showed low to 147 
absent proliferative responses to JCV peptides, were negative for urinary JCV viral 148 
DNA, but produced large amounts of anti-JCV VP1 antibodies. JCV-specific T cell 149 
responses were also reduced in individuals expressing DRB1*01:01. Our data are of 150 
interest in the context of vaccine development and studies of the cellular immune 151 
responses against JCV under physiological and pathological conditions. 152 
153 
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Material and Methods 154 
Donors  155 
 49 HD were recruited from the Blood Bank at the University Medical Center 156 
Hamburg-Eppendorf, Germany, forming cohort 1 (Table 1). The mean age of the donors 157 
was 46.5 years (range 23 to 72 years), and the gender distribution was 28 females and 158 
21 males. Cohort 1 was used to determine the peripheral cellular response to JCV 159 
peptide pools, individual peptides and JCV VP1 virus-like-particles (VLP). The humoral 160 
response to JCV VLP was assessed by testing the supernatant fluids obtained after 161 
Ficoll density centrifugation in this cohort, since we did not have access to serum 162 
samples from these donors. Cohort 2 contains 22 HD recruited from our institute staff 163 
and with a mean age of 35.4 years (range 26 to 46 years) (Table 1). The gender 164 
distribution in cohort 2 was 15 females and 5 males. Cohort 2 was employed to 165 
investigate urinary viral shedding and the relation between T cell responses and the 166 
presence of JCV-specific IgG antibodies in serum. The study was approved by the local 167 
ethics committee (Ethik-Kommission der Ärztekammer Hamburg, No. 2758), and 168 
informed consent was obtained from all study subjects. 169 
 170 
HLA typing 171 
 All individuals in cohort 1 and 2 were typed for HLA class II molecules at the HLA 172 
laboratory, University Medical Center Hamburg-Eppendorf, Germany. Isolation of DNA 173 
was performed with the help of QiaCubeTM (Qiagen GmbH, Hilden, Germany) from 174 
whole blood with a final concentration of 30 ng/µl. The samples were high resolution 175 
typed for HLA class II (DRB1*, DRB3*, DRB4*, DRB5*, DQA1* and DQB1*) with a 176 
sequence-specific oligonucleotide (SSO)-based test Dynal-RELITM-SSO (Invitrogen 177 
GmbH, Karlsruhe, Germany) and with the sequencing-based typing kit AlleleSEQRTM 178 
HLA-SBT (Abbott Molecular, Wiesbaden, Germany). HLA class II types are listed in 179 
Table S1 (cohort 1) and Table S2 (cohort 2). Frequencies of HLA class II alleles among 180 
cohort 1 and 2 are summarized in Table S3. 181 
 182 
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JCV sequence analyses 183 
 JCV sequences available in all databanks were retrieved and analyzed by using 184 
the HUSAR software package (53). The amino acid sequences of all proteins (VP1, 185 
VP2, VP3, agnoprotein, LTAg and STAg) from all nine human polyomaviruses were 186 
extracted from reference genomes available in GenBank, i.e. BKV (accession number 187 
NC_001538), JCV (NC_001699), KIV (NC_009238), WUV (NC_009539), MCV 188 
(NC_010277), TSV (NC_014361), HPyV6 (NC_014406), HPyV7 (NC_014407), HPyV9 189 
(NC_015150). Each of the corresponding proteins derived from all human polyomavirus 190 
reference genomes were aligned with the ClustalW program (60). Furthermore, 479 191 
VP1 amino acid sequences were aligned. Conservation of the sequence alignments 192 
was plotted with the Plotcon program from the EMBOSS software package (50) by 193 
using a window size of 25. All multiple sequence alignments can be provided by the 194 
authors upon request. Maximum sequence similarity of immunodominant JCV peptides 195 
was calculated by using epitope conservancy analysis from the IEDB and analysis 196 
resource (www.immuneepitope.org) (65).  197 
 198 
Proteins and peptides 199 
 For the identification of JCV-specific CD4+ T cells, 204 (13-16-mer) peptides 200 
covering the entire JC viral proteome (Fig. 1A) were applied. Peptides were synthesized 201 
and provided by pe (peptides and elephants GmbH, Potsdam, Germany). The peptides 202 
overlap by 5 amino acids and include 35 peptides with common single amino acid 203 
mutations (Table S4). To account for amino acid variations (Fig. 1B), that occur among 204 
the different JCV genotypes and strains, amino acid sequences of each JCV-encoded 205 
protein including agnoprotein (Agno), VP1, VP2, VP3, large T antigen (LTAg), small T 206 
antigen (STAg) and three T’ antigens (T’135, T’136 and T’165) from all 479 JCV 207 
genomic sequences available in GenBank (by March 2008) were aligned with the 208 
ClustalW program (60) and those polymorphisms, which were prevalent in more than 209 
1% of all retrieved sequences, were defined as common mutations. Peptides were 210 
arranged in a set of 42 pools, each pool containing 5 different peptides (Fig. 1C, Table 211 
S5). Variations of the same peptide were not arranged in the same pool. 212 
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JCV VP1 protein forms virus-like (VLP) particles, and VP1 and VLP are therefore used 213 
as interchangeable terms. VP1 protein forming VLP (VP1/VLP) was generated by the 214 
Life Science Inkubator, Bonn, Germany, as previously described (22). Tetanus toxoid 215 
(TTxd) (Novartis Behring, Marburg, Germany) was used as positive control. 216 
 217 
Proliferation and activation assays 218 
 Peripheral blood mononuclear cells (PBMC) were separated by Ficoll density 219 
gradient centrifugation (PAA, Pasching, Austria), always using the same volume/volume 220 
ratio of blood/Ficoll. Proliferation against peptide pools was performed with fresh PBMC 221 
and proliferative assays with individual peptides with frozen cells from the same 222 
individuals from the same date of sampling. In both assays T cell responses to VLP, 223 
TTxd and PHA were also analyzed. 2 x 105 PBMC per well were seeded in 96-well U-224 
bottom microtiter plates in RPMI (Invitrogen, California, USA) containing 2 mM 225 
glutamine, 50 µg/ml gentamicin, 100 U/ml penicillin/streptomycin (all from Whittaker 226 
Bioproducts, California, USA) and 5% pooled human AB serum. JCV peptide pools, 227 
JCV individual peptides, VLP or TTxd were added to the cultures and cells were 228 
cultured for seven days. PHA-L (1 µg/ml, Sigma, St Louis, MO) was added to some 229 
wells on day four. Wells containing only cells and medium served as negative controls. 230 
All JCV peptides were either tested in pools at a final concentration of 2 µM per peptide 231 
or as individual peptides at a concentration of 10 µM. TTxd was tested at 5 µg/ml. To 232 
detect frequencies of JCV-specific cells lower than 1 in 2 x 105 PBMC, 8 replicate wells 233 
were seeded for each peptide pool. Individual peptides were tested by seeding 10 wells 234 
per peptide. To control for variability between 96-well U-bottom microtiter plates in each 235 
HD, each plate contained wells stimulated with JCV peptides, PHA, TTxd and VLP, as 236 
well as unstimulated wells. 237 
 After seven days of incubation, proliferation was measured by 3H-thymidine 238 
(Hartmann Analytic, Braunschweig, Germany) incorporation in a scintillation beta 239 
counter (Wallac 1450, PerkinElmer, Rodgau-Jürgesheim, Germany). The stimulation 240 
index (SI) was calculated as SI = counts per minute (cpm) of an individual well with 241 
antigen / mean cpm of 72 negative control wells. Individual wells with peptide pools 242 
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were considered positive if SI was >3 (Fig. 2A). In order to detect reactivity of thawed 243 
cells against single peptides we considered positive individual wells, with SI > 2. 244 
 To determine, whether preferentially CD4+ or CD8+ T cells or both of these T cell 245 
subsets equally were stimulated by the above described JCV-derived 13-16-mer 246 
peptides, representative blood samples from cohort 1 were analyzed by using 247 
carboxyfluorescein succinimidyl ester (CFSE, Sigma, St Louis, USA) dye dilution for 248 
proliferation and by intracellular cytokine staining (ICS) using interferon-γ (IFN-γ) for 249 
activation. Briefly, 107 PBMCs/ml were incubated with 0.5 µM CFSE for eight minutes at 250 
room temperature, labeling was stopped by 33.3% fetal calf serum and unbound CFSE 251 
was washed out. 2 x 105 CFSE-labeled PBMC per well were seeded in 96-well U-252 
bottom plates in above mentioned medium. For each donor, two JCV peptide pools, 253 
which had been identified as immunodominant in the respective donor by 3H-thymidine 254 
incorporation assays, were selected for stimulation and, for each peptide pool, 20 wells 255 
were stimulated at a final concentration of 2 µM per peptide. Six wells were plated 256 
without antigen to serve as negative control. TTxd at 5 µg/ml served as positive control. 257 
After 10 - 14 days, five JCV peptide-stimulated wells were pooled and processed for 258 
IFN-γ ICS. Therefore, the respective wells were restimulated with the corresponding 259 
JCV peptide pool at a final concentration of 2 µM for each peptide, and after 1h of 260 
incubation at 37°C Golgistop (BD Biosciences, Heidelberg, Germany) was added, 261 
followed by incubation for 5 h at 37°C. After washing twice with PBS, cells were labeled 262 
with Live/Dead Fixable Aqua Dead Cell Stain Kit (Invitrogen, GmbH, Karlsruhe, 263 
Germany). After blocking cellular Fc receptors with human IgG (Sigma, St Louis, USA), 264 
following surface markers were stained with antibodies: CD3 (PE, clone SK7, 265 
Biolegend, London, UK), CD4 (APC, clone RPA-T4, eBioscience, San Diego, USA) and 266 
CD8 (PB, clone DK25, Dako, Glostrup, Denmark). Cells were fixed and permeabilized 267 
with Cytofix/Cytoperm (BD Biosciences) according to manufacturer’s protocol, washed, 268 
and stained with an anti-IFN-γ antibody (PE-cy7, clone 4S.B3, BD Biosciences). Cells 269 
were washed twice with 200 µl FACS buffer (0.01% sodium azide and 1% bovine serum 270 
albumine in PBS) before samples were analyzed with a LSR-II flow cytometer (BD 271 
Biosciences) and FACS Diva Software (BD Biosciences), gating on lymphocytes, singlet 272 
cells, live cells, CD3+ cells, CD4+ and CD8+ cells, CFSEdim and IFN-γ+ cells (Fig. S1A). 273 
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Approximately 30,000 singlet, live, CD3+ lymphocytes were recorded per sample. The 274 
stimulation index for CFSE labeled cells was calculated as SI [CFSE] = percentage of 275 
CFSEdim T cells among a pooled set of five wells with antigens / percentage of CFSEdim 276 
T cells among a pool of six unstimulated control wells (Fig. 2B and Fig. S1B). The 277 
stimulation index for IFN-γ ICS was calculated as SI [IFN-γ] = percentage of IFN-γ+ T 278 
cells among a pooled set of five wells with antigens / percentage of IFN-γ+ T cells 279 
among a pool of six unstimulated control wells (Fig. 2B and Fig. S1B).  280 
 281 
ELISA for VP1/VLP-specific antibodies  282 
 The level of JCV VP1/VLP-specific IgG antibodies was determined as described 283 
previously (66). Briefly, ELISA plates were coated with 100 µl JCV VLP (1 mg/ml)/well 284 
and incubated with serum samples or Ficoll supernatant, diluted 1:5000 in blocking 285 
buffer (5% non-fat powdered milk in 25mM Tris 150mM NaCl), and serial dilutions of a 286 
positive control. Human IgG was captured by a biotin-conjugated anti-human Fc 287 
antibody (eBioscience, Frankfurt, Germany) and detected by an avidin horseradish 288 
peroxidase (eBioscience, Frankfurt, Germany). Extinction was measured as optical 289 
density at 450 nm (OD450) using a µQuant microplate reader (Perkin Elmer, Waltham, 290 
MA, USA). The measured extinctions were normalized to the OD450 of the positive 291 
control on the plate and reported as normalized OD450 (nOD450 = mean OD450 of sample 292 
replicates / mean OD450 of positive control replicates on the plate). The same human 293 
serum was always used as positive control and its reactivity approximated an OD450 of 294 
1. To check comparability between Ficoll supernatants and sera, JCV-specific antibody 295 
levels were measured in sera and Ficoll supernatants of three healthy donors, from 296 
whom sera and whole blood for Ficoll gradient centrifugation was collected at the same 297 
time. Ficoll supernatant showed reproducibly a dilution factor of 1.2 in comparison to the 298 
serum sample from the same donor. 299 
In order to determine serological cross-reactivity between JCV and BKV VP1 300 
proteins (kindly provided by Natalie Meinerz and Robert Garcea, Department of 301 
Molecular, Cellular, and Developmental Biology, University of Colorado Boulder, USA), 302 
representative serum samples underwent competitive inhibition (“pre-adsorption”) 303 
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assays. Specifically, serial dilutions of BKV VP1 and JCV VP1 proteins were added to a 304 
1:5000 dilution of serum in blocking buffer and incubated for 1 h at 4°C prior to 305 
incubating samples with immobilized JCV VP1 and completing the ELISA as described 306 
previously (66). The concentration needed to sufficiently and reliably compete VP1-307 
specific antibodies was 4.86 µg/ml. Percent inhibition (PI) was calculated as PI = 100 x 308 
[1 - (average nOD450 VP1 pre-incubated samples / average nOD450 buffer incubated 309 
samples)]. 310 
 311 
Quantitative PCR assay for JCV detection 312 
 The JCV DNA load was quantified in urine by applying a quantitative PCR 313 
(qPCR) with a set of primers and probe located at the T antigen of JCV (49). Viral DNA 314 
was extracted from 750 µl of urine by applying the QIAampUltraSens Virus Kit (Qiagen, 315 
Hilden, Germany). Nucleic acids were recovered in 60 µl of elution buffer. Thus, in a 316 
qPCR reaction, 125 µl of urine were analyzed. The assay was specific for JCV detection 317 
and the lower limit of JCV DNA detection was 1-10 copies per reaction, with a linear 318 
range from 102 to 107 genome copies per reaction. Amplifications were performed in a 319 
25 µl reaction mixture containing 10 µl of sample and 12.5 µl of TaqMan® Environmental 320 
Master Mix 2.0 (Applied Biosystems, Madrid, Spain) which offers accurate, real-time 321 
PCR-based pathogen detection and is highly sensitive even in the presence of 322 
inhibitors. The concentration of each primer (JE3R and JE3F) was 0.9 µM and 323 
fluorogenic probe (JE3P) 0.225 µM. This primer/probe set is specific for JCV and does 324 
not detect human polyomaviruses BK PyV nor SV40 or bovine polyomavirus (49). 325 
Following activation of the AmpliTaq Gold for 10 min at 95ºC, 40 cycles (15s at 95ºC 326 
and 1 min at 60ºC) were performed in aMx3000P detection system (Stratagene, Santa 327 
Clara, USA). Neat and a ten-fold dilution of the samples were run in duplicates (4 328 
runs/sample), whereas each dilution of standard DNA suspension (from 102 to 107) was 329 
run in triplicate. In all qPCR assays the amount of DNA was defined as the mean of the 330 
data obtained. A non-template control (NTC) was added to each run in addition to the 331 
negative control of the nucleic acid extraction. The possible presence of inhibitors, 332 
potentially leading to false negative results, has been tested adding low copy numbers 333 
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of viral DNA to urine samples. JCV Mad1 cloned into the EcoRI site of a pBR322 vector 334 
was used for the standard curve. All qPCRs were done in different rooms isolated from 335 
post-PCR samples to prevent contamination. 336 
337 
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Results 338 
JCV-specific immune response in healthy donors 339 
 In order to study the CD4+ T cellular immune response to JCV, 204 13-16-mer 340 
peptides overlapping by 5 amino acids and spanning all JCV proteins (Agno, VP1, VP2, 341 
VP3, LTAg, STAg and T’ antigens T’135, T’136 and T’165) were synthesized and 342 
arranged in 42 pools (Fig. 1A-C, and Table S5). PBMC from 49 HD (cohort 1) were 343 
tested for antigen-specific proliferation against the 42 pools. T cell responses showed a 344 
high degree of inter-individual variability with respect to recognition of different peptide 345 
pools, the magnitude of the proliferative response, i.e. the stimulation indices of 346 
individual proliferating wells, and also with respect to the number of positive wells 347 
responding to a single pool (Fig. 2A). Each of the above measures contains different 348 
information about JCV-specific T cell responses. First, the number of different pools that 349 
elicit a proliferative response in a given donor expresses whether the JCV-specific T cell 350 
response is broad, when many peptide pools are recognized, or focused, if only a few or 351 
one pool are positive. Second, the magnitude of the response (i.e. stimulation index) 352 
expresses the amount of incorporated thymidine and hence indirectly the number of cell 353 
divisions. And third, since a defined number of PBMC is seeded per well, the number of 354 
positive wells per pool serves as a measure of the presence in a predefined amount of 355 
cells serving as a very rough approximation of the precursor frequency of antigen-356 
specific T cells. These 3 measures together allow assessing the JCV-specific immune 357 
response within a single individual. Regarding our data, PBMC from some of the HD 358 
failed to proliferate against any of the peptide pools (Fig. 2A, upper graph), while others 359 
showed a strong proliferative response against multiple peptide pools (Fig. 2A, lower 360 
graph). The mean SI of negative control wells and tetanus toxoid (TTxd)-stimulated 361 
wells of the same individuals are shown in the right graphs. CFSE labeling and IFN-γ 362 
ICS of PBMCs from representative donors confirmed, that CD4+ T cells, and not CD8+ T 363 
cells, preferentially responded to stimulation with donor-specific immunodominant JCV 364 
peptide pools as identified by 3H-thymidine incorporation assays (Fig. 2B and Fig. S1B). 365 
CFSEdim cells representing proliferated cells were predominantly activated upon 366 
restimulation with JCV peptides as shown by IFN-γ secretion in the ICS, and IFN-γ 367 
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secreting cells were predominantly CFSEdim. Since 3H-thymidine incorporation assays 368 
are more convenient for the analysis of such a high number of peptide pools and 369 
donors, we decided to analyze the fine-specificity of JCV-specific CD4+ T cells in-depth 370 
by using 3H-thymidine incorporation assays. 371 
We also analyzed the JCV-specific humoral response and shedding of JCV DNA 372 
in urine. VLP-specific antibodies were quantified by ELISA in 44 HD. JCV DNA was 373 
determined by PCR in urine from 22 HD. JCV-specific humoral responses and shedding 374 
of JCV DNA in urine also showed a high degree of inter-individual variability (Fig. 2C 375 
and D). Considering a dilution factor of 1.2 for Ficoll supernatant related to serum, 376 
nOD450 values among Ficoll supernatants of cohort 1 and sera of cohort 2 showed 377 
similar variability (Fig. 2C). Displayed are the urinary JCV DNA copy numbers of all 10 378 
JCV-excreting individuals (Fig. 2D).  379 
Next, in order to examine whether JCV-specific T cellular immune responses are 380 
indicative of JC virus infection, we calculated the percentage of HD with positive T cell 381 
response to JCV and compared this value with the percentage of HD presenting VLP-382 
specific antibodies and with JCV DNA in urine. The latter are both parameters currently 383 
used to identify JCV-infected individuals. To calculate the percentage of HD with 384 
positive JCV-specific T cell responses we used two different arbitrary thresholds for 385 
positivity. The low threshold considers that a HD has a positive JCV T cell response, if 386 
she/he shows 3 or more wells with SI ≥ 3, while the high threshold considers 10 or more 387 
wells with SI ≥ 3. Analogous thresholds were used to determine the percentage of HD 388 
with VLP-specific antibodies (low threshold at nOD450 ≥ 0.08; high threshold at nOD450 ≥ 389 
0.2) and with JCV DNA in urine (low threshold at copy number ≥ 10 GC/ml; low 390 
threshold at copy number ≥ 100 GC/ml). Using the low thresholds for positivity, 77.6% of 391 
the HD were positive for JCV-specific T cell response compared to 89.4% for anti-VLP 392 
antibodies, and only 45.5% of HD shedding JCV DNA in urine. Using the high 393 
thresholds 28.6% of HD were positive for JCV-specific T cell response, 42.6% for anti-394 
VLP antibodies and 36.4% for JCV DNA in urine. Considering a low threshold of nOD450 395 
≥ 0.08 for the definition of seropositive donors, 33.3% of seropositive individuals 396 
showed no T cell proliferation to JCV peptides (defined as less than 3 wells with SI ≥ 3). 397 
45,5% of seropositive donors showed no T cell proliferation to JCV peptides, when a 398 
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high threshold of nOD450 ≥ 0.2 was applied. The association between JCV-specific 399 
antibody level and urinary JC viral load was weak (correlation coefficient r=0.27), similar 400 
to the results published by Gorelik et al. (23). As a result of the use of two cohorts, 401 
measures of all the three parameters in the same HD that would allow us to study 402 
correlations are not available. This was due to using healthy blood bank donors, from 403 
whom serum and urine could not be obtained. 404 
 405 
Identification of JCV immunodominant epitopes 406 
First, we analyzed T cell responses from the 49 HD of cohort 1 against the 42 407 
peptide pools. Individuals responded to peptide pools from all JCV proteins (Fig. S2). 408 
The preference and strength of reactivity against peptide pools from a specific JCV 409 
protein varied between HD (Fig. S3). Most donors recognized pools derived from four 410 
different JCV proteins (36.7%), some donors recognized three different proteins 411 
(20.4%), and only 12.2% of all HD recognized peptide pools derived from all JCV-412 
encoded proteins.  413 
To determine the JCV peptide pools that likely contained immunodominant 414 
peptides, we performed a detailed analysis of T cell responses of cohort 1. Responses 415 
of individual wells were considered positive when the SI was higher than 3. First, the 416 
sum of SIs (∑(SI>3)) from positive wells was calculated to account for strength and 417 
proliferative capacity of each donor to each peptide pool (Fig. 3A, upper graph). To 418 
correct for background proliferation, we calculated the ∑(SI>3) also for unstimulated 419 
wells, normalized the value for the number of wells and subtracted it from the ∑(SI>3) 420 
corresponding to each pool and donor. Next, in order to integrate an estimation of the 421 
precursor frequency of JCV-peptide-specific T cells, we calculated the fraction of 422 
positive wells (number of total positive peptide wells (SI>3) per number seeded wells) 423 
(Fig. 3A, middle graph). Again, with the purpose to exclude background proliferation, the 424 
fraction of unstimulated wells with SI>3 was calculated, normalized and subtracted from 425 
the fraction of positive peptide-stimulated wells. Finally, we determined as a third 426 
indicator of immunogenicity the frequency of donors with at least one positive well for 427 
each pool (Fig. 3A, lower graph). Using these three parameters we created a reactivity 428 
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score (RS = ∑(SI>3) x percentage of reactive wells x percentage of reactive individuals) 429 
for each pool that takes into account the stimulatory capacity of the pool, the frequency 430 
of peptide-specific cells in the pool and the frequency of donors with at least one well 431 
positive for the pool (Fig. 3B). Using this approach we identified pool 14 (containing VP1 432 
peptides), 17 (containing VP2 peptides), 32 and 33 (containing LTAg peptides) as the 433 
pools showing higher RS and in consequence to be the best candidates to contain 434 
immunodominant peptides. These pools had a ∑SI>3 higher than 125 with a percentage 435 
of reactive wells of at least 5.0% and recognition by more than 30% of HD.  436 
 Although the use of 15-mer peptides in combination with the settings of the 437 
proliferative assay favors detection of CD4+ T cell responses according to current 438 
knowledge, we cannot exclude contribution of CD8+ T cells in the proliferative response 439 
to pools 14, 17, 32 and 33 since 15-mer peptides can be shortened by proteolytic 440 
cleavage and presented on HLA class I molecules.  441 
 To identify immunodominant JCV peptides, we tested PBMC from 20 HD (cohort 442 
2) with the 20 individual peptides contained in pools 14, 17, 32 and 33. Reactivity 443 
scores for each individual peptide were calculated as mentioned above, but considering 444 
positive a response with SI>2, since we used fewer cells per plate (100.000/well) due to 445 
a limited amount of cells and cells had been frozen before their use. Accordingly, a 446 
lower proliferative capacity of the cells enrolled in these assays along with 447 
correspondingly less background proliferation appeared. Results are summarized in Fig. 448 
3C. We identified peptide 41 (VP1 (123-137) variant 3; V3) as the immunodominant 449 
peptide contained in pool 14, and peptides 81 (VP2 (30-43)) and 82 (VP2 (39-51)) as 450 
the immunodominant peptides contained in pool 17. Pool 33 contained the 451 
immunodominant peptide 162 (LTAg (415-429)). We were not able to identify an 452 
immunodominant peptide in pool 32.  453 
 454 
HLA class II restriction of JCV-specific cellular immune responses  455 
 CD4+ T cells recognize antigenic peptides in the context of HLA class II 456 
molecules. Table S1 shows the HLA class II alleles of the 49 HD from cohort 1. HD 457 
were divided into twelve groups depending on HLA-DR expression (Table S3). Group 458 
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DR1 included all donors expressing the HLA-DRB1*01 alleles (n=8), and similarly we 459 
grouped donors expressing HLA-class II molecules of the major subtypes DRB1*04  460 
(n=15, DR4), DRB1*07 (n=13, DR7), DRB1*08 (n=2, DR8), DRB1*10 (n=1, DR10), 461 
DRB1*11 (n=9, DR11), DRB1*12 (n=4, DR12), DRB1*13 (n=12, DR13), DRB1*14 (n=1, 462 
DR14), DRB1*15 (n=13, DR15), DRB1*16 (n=7, DR16), and DRB1*03 (n=10, referred 463 
to as DR17). The circle diagram in Fig. 4A represents the frequency of the most 464 
common DR types within this HD cohort. It is important to note, that nearly all donors 465 
were heterozygote for HLA-DRB1*alleles, and are therefore contained in two different 466 
HLA-DR groups. Proliferative responses were analyzed for HLA-DRB1* cohorts, which 467 
were represented by at least 8 individuals. To analyze the T cell response of each HD 468 
group against the 42 pools we calculated the RS as described above. Because each 469 
group was made up by different numbers of HD, we normalized each group for the 470 
number of donors, therefore, values are directly comparable and adjusted to n=10. 471 
PBMC from HD expressing different HLA class II molecules responded to different 472 
peptide pools (Fig. 4B) and also the RS varied considerably among groups. HD from 473 
groups DR7 and DR17 showed significantly higher RS to JCV peptides, than HD from 474 
groups DR1 and DR4, while no differences were observed in RS to TTxd (Fig. 4C and 475 
D). The preference for specific JCV proteins also varied among HLA-DR groups (Fig. 476 
S2 and Fig. S3). All HD except of DR13+ and DR16+ HD recognized peptides from the 477 
amino-terminal region of VP2 more often than expected (Fig. S2). Peptides from the 478 
carboxy-terminal region of VP2 were recognized less frequently than expected (Fig. 479 
S2). DR8+, DR12+ and DR13+ HD recognized peptides from the LTAg more often than 480 
expected (Fig. S2). Importantly, the preference for specific JCV proteins was also 481 
variable within a group expressing certain HLA alleles (Fig. S3), which is most likely due 482 
to the fact that there is variability with respect to the second HLA-DR allele expressed 483 
by the heterozygote donors. The pools inducing the strongest cellular response in the 484 
entire cohort (pools 14, 17, 32 and 33) were pools that were stimulatory in the context of 485 
several class II alleles including the two groups showing the strongest responses (group 486 
DR7 and group DR17) (Fig. 4B).  487 
Next, we examined whether the peptides identified as immunodominant after 488 
analyzing the whole HD cohort were also immunodominant for all HLA-DR haplotypes. 489 
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PBMC from cohort 2 expressing different HLA-class II alleles (Fig. 5A) were tested 490 
against the 20 peptides contained in the pools inducing the strongest cellular response 491 
in the entire cohort (pools 14, 17, 32 and 33). The reactivity scores induced by these 20 492 
peptides are summarized in Fig. 5B. The peptides inducing the highest RS clearly 493 
differed between HLA subgroups showing that HLA class II alleles contribute to the fine 494 
specificity of CD4+ T cells against JCV peptides. An important factor in determining 495 
immunodominance is binding to the respective HLA-class alleles, which can be 496 
predicted in silico by a number of publicly accessible databases. When we calculated 497 
the in silico-predicted binding scores by using the consensus method from the IEDB 498 
Analysis Resource (65), the binding scores of immunodominant JCV peptides varies 499 
broadly depending on the HLA allele (Table S6). Peptide 41 (VP1 (123-137) V3) was 500 
identified as immunodominant peptide in the whole cohort, probably because it was 501 
strongly stimulatory in DR11 and DR13 donors, who represented 50% of all tested 502 
individuals. Similarly, peptide 82 (VP2 (39-51)) was identified as immunodominant, most 503 
likely because it induced prominent responses in individuals expressing DR7 and DR17. 504 
Sequences for all immunodominant JCV peptides are summarized in Table 2. All 505 
peptides identified as immunodominant except for the two JCV VP1-derived peptides 506 
showed highest sequence similarity with BKV-encoded protein sequences (mean 507 
similarity 78.4%, range 53.3 – 100%), when compared to all human PyV (Table 2). 508 
BKV-derived peptides previously described as immunodominant and/or cross-reactive 509 
to JCV were found to match to peptides from immunodominant pools 32 and 33 (LTAg) 510 
and peptides from substantially recognized pools 4, 5, 6, 35 and 38 of the present study 511 
(Table S7 and Table S8). 512 
 513 
Reduced cellular JCV-specific T cell immune response in DRB1*04:01+ donors 514 
A more detailed analysis of HD from the DRB1*04+ group revealed marked differences 515 
in JCV-specific T cell responses. The RS of HD expressing the DRB1*04:01 allele were 516 
significantly lower than those of HD expressing other DRB1*04 alleles (Fig. 6A and B) 517 
or non-DR4 alleles (Fig. 4C). Interestingly, this reduced T cell responsiveness was 518 
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“specific” for JCV, since the response to the recall antigen TTxd in these donors was 519 
comparable to those of HD expressing other DRB1*04 molecules (Fig. 6C). 520 
 In order to examine further the reduced JCV T cell response in DRB1*04:01+  521 
donors, we determined the presence of JCV DNA in urine samples from eight 522 
DRB1*04:01+ donors, from seven expressing other DR4 alleles and from 10 HD not 523 
expressing any DR4 allele. Results are summarized in Fig. 6D. Remarkably, none of the 524 
urine samples from HD expressing the DRB1*04:01 allele tested positive for JCV DNA. 525 
In contrast, JCV DNA was detected in 4 out of 5 (80.0%) urine samples from HD 526 
expressing DR4 alleles other than DRB1*04:01 and in 6 out of 10 (60.0%) from donors 527 
not expressing DR4 alleles (Fig. 6D). These results together with the low frequency of 528 
JCV-specific T cells in DRB1*04:01+ HD suggested that these individuals might not 529 
have been exposed to the virus. To examine this issue further, we then tested the 530 
humoral response against JCV VP1 by ELISA to assess their infectious state in serum 531 
samples from seven DRB1*04:01+ donors, five HD expressing DR4 alleles other than 532 
DRB1*04:01 and from 10 HD not expressing any DR4 allele. DRB1*04:01+ donors 533 
showed similar or even higher levels of anti-JCV antibodies compared to the two other 534 
groups (Fig. 6E). Serological cross-reactivity against BKV VP1 was excluded by 535 
competitive pre-adsorption assays (Fig. 6F). Reactivity of serum samples from five 536 
DRB1*04:01+ donors was efficiently inhibited by pre-incubation with 4.86 µg/ml JCV 537 
VP1 (median PI, 64.9%; interquartile range [IQR], 58.5 to 68.6%; minimum inhibition, 538 
52.1%) and was minimally inhibited by 4.86 µg/ml BKV VP1 (median PI, 1.4%, IQR, 0.0 539 
to 2.2%; maximum inhibition, 3.0%). Similarly, serum samples from seven DRB1*04:01– 540 
donors, including three HD expressing DR4 alleles other than DRB1*04:01, showed 541 
strong inhibition after pre-incubation with 4.86 µg/ml JCV VP1 (median PI, 83.7%; 542 
interquartile range [IQR], 68.3 to 88.2%; minimum inhibition, 52.2%), but minimal 543 
inhibition after pre-adsorption with 4.86 µg/ml BKV VP1 (median PI, 1.5%, IQR, 0.0 to 544 
6.9%; maximum inhibition, 12.3%). Using a threshold of nOD450 ≥ 0.08 for the definition 545 
of seropositive HD, 27.8% of DRB1*04:01– donors and 44.4% of DRB1*04:01+ 546 
individuals showed no T cell proliferation to JCV peptides (less than 3 wells with SI ≥ 3 547 
per donor). Using the higher threshold for seropositivity (nOD450 ≥ 0.2), even 60% of 548 
DRB1*04:01+, but only 33.3% of DRB1*04:01– donors showed no T cell proliferation. 549 
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The anti-JCV VP1 seropositivity strongly argues against the hypothesis that these 550 
donors were not exposed to JCV, but, despite the weak CD4+ T cell responses against 551 
JCV peptide pools, showed a robust antibody response against the major capsid protein 552 
from as yet unknown mechanisms 553 
 554 
Reduced cellular JCV-specific immune responses in DRB1*01:01+ healthy donors 555 
Similar to DRB1*04:01-heterozygous donors, HD positive for DRB1*01+ mounted 556 
significantly weaker JCV-specific cellular responses than DR7+, DR15+ and DR17+ HD 557 
(Fig. 4B and 5C), although cellular reactivity against TTxd did not differ among these 558 
groups (Fig. 4D). Unfortunately, we could not analyze urinary shedding or JCV-specific 559 
humoral response in DR1+ HD because of lack of samples. 560 
561 
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Discussion 562 
 In the present study we examined the cellular immune response against JCV with 563 
respect to prevalence of positive CD4+ T cell responses, specificity for JCV 564 
proteins/peptides and relation to HLA-class II haplotype of the donor to develop a better 565 
understanding of JCV-specific immune control, to identify potential risk factors for PML 566 
and as a basis for future vaccination approaches. We identified several 567 
immunodominant peptides within the most prominent peptide pools, peptide 41 (pool 568 
14), peptides 81 and 82 (pool 17), peptide 155 (pool 32), and peptide 162 in pool 33 569 
(Fig. 3C). However, after stratification for HLA-class II haplotypes differences in the 570 
responses to peptides pools as well as to individual peptides within these pools became 571 
visible (Fig. 4). While the magnitude of the response to the pools differed for example 572 
between individuals carrying DR15 and DR17 alleles versus those carrying DR1 and 573 
even more so DR4 alleles, the focus of the response remained on VP1 across different 574 
HLA-DR haplotypes (Fig. 4). At the level of individual peptides, HLA stratification 575 
revealed that the immunodominant single peptides within the immunodominant pools 576 
differed according to the donors’ HLA-DR haplotype. This is not too surprising when 577 
considering that the peptide binding grooves of the main alleles show considerable 578 
differences with respect to their binding motifs. In this context it has to be mentioned 579 
that we did not formally establish HLA-restricted peptide recognition, which needs to be 580 
done with T cell lines or -clones and antigen-presenting cells, e.g. HLA-DR 581 
transfectants, matched for each individual HLA-DR molecule. Such a detailed analysis 582 
is not possible at the level of the entire JCV proteome and across several HLA-DR 583 
haplotypes, however, our data should provide a basis for future studies in this direction. 584 
 Next we examined the question if JCV-specific cellular immune responses are 585 
comparable to VLP seropositivity or if there are substantial differences. Since there is at 586 
present no commonly established definition for what constitutes a positive T cell 587 
response to JCV and hence indicative if the individual has been exposed to the virus, 588 
we arbitrarily defined thresholds for the cellular immune response against JCV peptides 589 
or JCV VLP, for urinary viral shedding, and for the humoral immune response. To 590 
determine if an individual shows a positive JCV-specific T cell response we took into 591 
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account the fraction of JCV peptide pool-reactive wells. We found positive cellular 592 
response to JCV in 28.6 - 77.6% depending on the threshold. Other ways to determine 593 
the status of exposure to or infection with JCV are urinary excretion and the presence of 594 
JCV-specific antibodies. Here we found a positivity ranging from 36.4 - 45.5% (urinary 595 
excretion) and 42.6 - 89.4% (anti-VP1 antibody response), depending on the threshold 596 
and criterion. Since only approximately 50% of JCV-exposed individuals shed virus in 597 
the urine, ascertainment of JCV exposure cannot be based on JCV urinary excretion 598 
alone. On the other hand, an individual, who sheds virus in the urine, must be JCV 599 
infected even if JCV-specific T cell- or antibody responses are low or borderline. Based 600 
on our thresholds for positive T cell- and antibody responses, we assume that JCV 601 
exposure in our cohort ranged between between 60 and 80%. However, to formally 602 
address this issue, much larger cohorts need to be examined and compared 603 
systematically.  604 
 The protein triggering the highest overall proliferation is the major capsid protein 605 
VP1 and the amino-terminal end of the minor capsid protein VP2 (Fig. 3A, B). However, 606 
most donors also recognized other JCV proteins (Fig. S3), and the preference for a JCV 607 
protein varied not only among individual donors, but also among groups that had been 608 
stratified according to HLA-class II haplotype (Fig. S2 and Fig. S3).  609 
 As already mentioned above, when assessing immunodominance we considered 610 
the strength of the proliferative responses and the precursor frequency of antigen-611 
specific T cells. The latter measure expresses the fraction of T cells of an individual that 612 
is specific for JCV, while the prevalence of immunity in a population provides 613 
information as to what fraction of a population responds to a specific antigen. All three 614 
measures provide distinct information and can be used to determine 615 
immunodominance. Only peptide pools fulfilling all three criteria for immunodominance 616 
were considered here and the peptides within these pools were investigated 617 
individually. With this strategy, we found peptides 41 (VP1 (123-137), 618 
SNGQASHDNGAGKPV) and 82 (VP2 (39-51), EVEIASLATVEGI) causing strong 619 
proliferation in the entire cohort of HD. Peptides 81 and 82, as well as peptides 154 and 620 
155 overlap by 5aa, which may in part explain the proliferation to both. It is possible that 621 
the optimal and most stimulatory peptide is situated between peptide 81 and 82, or 622 
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between other peptides, that were not identified here, due to the overlap of only 5aa. 623 
However, the broad specificity of the CD4+ T cell responses indicates that multiple JCV 624 
peptides can be recognized by Caucasian individuals, and this is consistent with the fact 625 
that JCV is a highly prevalent virus, to which the human immune system is well 626 
adapted.  627 
 Previously, two CD8+ T cell epitopes, peptides VP1 (100-109) and VP1 (36-44), 628 
have been described as immunodominant in HLA-A*0201-restricted donors (12, 31). In 629 
our study, the VP1 (100-109) peptide (ILMWEAVTL) is represented by peptides 31 630 
(VP1 (91-105); LNEDLTCGNILMWEA) and peptide 32 (VP1 (101-115); 631 
LMWEAVTLKTEVIGV) in peptide pool 6. The VP1 (36-44) peptide (SITEVECFL) is 632 
covered by the peptide 20 (VP1 (34-48); VDSITEVECFLTPEM) in pool 4. Both pools 4 633 
and 6 were among the 12 and 6 pools respectively that elicited the strongest responses 634 
(Fig. 3B), and DR15+ and DR17+ individuals recognized pool 6 as the second strongest 635 
and strongest pool, respectively (Fig. 4B). Further support for the relevance of peptide 636 
VP1 (36-44) and peptide 20 from pool 4 (together with only 7 other JCV peptides) 637 
comes from our recent data that these peptides are relevant targets for brain-infiltrating 638 
CD4+ T cells that had been isolated from a brain biopsy of a patient suffering from PML-639 
immune reconstitution inflammatory syndrome (3). We also demonstrated CD8+ T cells 640 
recognizing JCV VP1 (36-44) in the brain biopsy of this HLA-A2+ MS patient, although 641 
the CD4+ T cells were more prevalent in the biopsy than CD8+ T cells. Data from the 642 
latter study and work presented here indicate that CD8+ T cells and CD4+ T cells 643 
recognize related epitopes and that the JCV peptide VP1 (36-44) is of particular 644 
relevance.  645 
 Regarding the influence of certain HLA-DR haplotypes on cellular immune 646 
responsiveness against JCV, the comparably very low or absent reactivity in 647 
DRB1*04:01+ individuals was of particular interest. Since all individuals in the two 648 
DRB1*04+ subgroups were heterozygote for DRB1*04:01 or DRB1*04:other except for 649 
one, and the effect of low proliferative response was not more pronounced in the 650 
homozygote DRB1*04:01+ individual, we conclude that the DRB1*04:01 haplotype has 651 
a dominant-negative influence on the JCV-specific proliferative response. It remains to 652 
be elucidated, which mechanisms lead to this gross reduction of JCV-specific T cell 653 
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responses in heterozygote DRB1*04:01+ HD. Several associations between HLA-654 
DRB1*04:01 and specific infections have been described in epidemiological studies, in 655 
which a considerable number of heterozygote donors was included:  HLA-DRB1*04:01 656 
was reported to be associated with slower progression of HIV-1 infection (32), clearance 657 
of chronic hepatitis C virus infection (38), and low hepatitis C virus activity (69). 658 
Furthermore, DRB1*04:01 is associated with increased risk for RA (45), mixed 659 
connective tissue disease (11) and insulin-dependent diabetes mellitus (57), as well as 660 
with a reduced age at onset of multiple sclerosis (MS) (68). DRB1*04:01+ MS patients 661 
show a restricted T cell receptor repertoire in the context of the T cell response to one 662 
immunodominant myelin basic protein (residues 111-129) peptide (43). Taken together, 663 
these reports appear to document dominant-positive effects of the HLA-DRB1*04:01 664 
allele. However, no experimentally proven domination of the DRB1*04:01 allele leading 665 
to reduced or abrogated function of other HLA-DR alleles has been reported. 666 
Previously, an HLA-associated low responsiveness to streptococcal antigen in healthy 667 
donors has been described and linked to the DR2-DQA1*0102-DQB1*0602(DQw6)-668 
Dw2 haplotype and DR2-DQA1*0103-DQB1*0601 (DQw6)-Dw12 haplotype (28, 46). 669 
One possible mechanism for such low responsiveness inherited in a dominant fashion is 670 
clonal deletion. A second mechanism could involve the deletion of JCV-specific T cells 671 
by chronic antigenic restimulation in situ. A third possibility is the induction of a T 672 
regulatory phenotype of JCV-specific T cells responding to HLA-DRB1*04:01+ antigen 673 
presenting cells. Whether the HLA-DRB1*04:01 allele itself or a immunosuppressive 674 
gene in strong linkage disequilibrium confers for this effect is of further interest, but 675 
remains to be clarified.  676 
 Additionally, we observed a B cell-skewed JCV-specific immune response in 677 
DRB1*04:01+ individuals. The mechanisms underlying a strong humoral anti-JCV 678 
response in HLA-DRB1*04:01-restricted donors and at the same time low to absent 679 
CD4+ T cell response remain to be elucidated. It could represent a T cell-independent 680 
JCV-specific B cell response with the second stimulation signal delivered by the JCV 681 
antigen itself, e.g. binding to Toll-like receptors or extensive cross-linking of the 682 
membrane. Such a T cell-independent virus-specific antibody response has been 683 
shown in mice lacking T cells and infected with mouse-PyV (56). A second mechanism 684 
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could involve a cross-reactive B-cell response, which recognizes not only JCV-encoded 685 
epitopes, but also similar epitopes encoded by other human polyomaviruses or 686 
infectious agents, which has been generated by CD4+ T cells specific against other 687 
human polyomaviruses or infectious agents, but not JCV. This mechanism could 688 
operate in the absence of JCV-specific CD4+ T cell responses and lead to JCV-specific 689 
B cell responses that are only detectable due to cross-reactivity between epitopes of 690 
JCV and other human polyomaviruses or other infectious agents.  691 
 Antibody cross-reactivity has been suggested between JCV and BKV VP1 692 
proteins (23), BKV and S40 VP1 proteins (29, 64), JCV and SV40 VP1 proteins (29, 693 
64). However, little or no antibody cross-reactivity between BKV and JCV VP1 proteins 694 
or between SV40 and both JCV and BKV VP1 proteins has been reported in the 695 
majority of studies (4, 15, 25, 36, 54, 55, 63, 64), and no antibody cross-reactivity was 696 
found between VP1 proteins of other polyomaviruses, e.g. Lymphotropic Polyomavirus 697 
(LPV) versus MCV or KIV versus WUV (29). Since we also did not find serum cross-698 
reactivity between JCV VP1 and its most related VP1 protein among human 699 
polyomaviruses (BKV VP1) in a representative set of sera from HLA-DRB1*04:01+ as 700 
well as from HLA-DRB1*04:01– donors, we expect the latter scenario to be less likely. 701 
 A third mechanism could be that the JCV-specific B cell response and a long-702 
lasting JCV-specific B cell memory had been generated with CD4+ T cell help earlier in 703 
life and that JCV-specific T cells had been deleted by chronic antigenic restimulation in 704 
situ. It is well known that the so-called Type 2 helper T cells (Th2) subset of CD4+ T cells 705 
activate B cells to provide neutralizing antibody production of various IgG isotypes by 706 
CD4+ T cell mediated production of interleukin (IL)-4 and IL-5 (42), whereas type 1 707 
helper T cells (Th1) cells producing IL-2 and interferon-γ (IFN-γ) favor clonal expansion 708 
of cytotoxic CD8+ T cells and macrophage activation. There are only few reports on an 709 
influence of MHC class II genes in shifting the CD4+ T cell phenotype in humans and 710 
thereby predetermining an immune response, which is skewed to be more cell- or more 711 
antibody-mediated. Agrewala and Wilkinson (1) showed that the p(91-110) epitope of 712 
the 16-kDa antigen of M. tuberculosis is able to elicit a Th1 or Th2 response depending 713 
on the HLA-DR haplotype of the donor. It was suggested, that a high MHC-peptide 714 
affinity leads to a Th1 response and lower binding affinities to a Th2 response (33, 44). 715 
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Wen et al. (67) showed in HLA-DR4 transgenic mice that DRB1*04:01-encoded 716 
molecules may promote a Th2 immune response. Furthermore, HLA-DRB1*04:01 has 717 
been associated with the development of antibodies against interferon-beta in MS 718 
patients and autoantibodies against insulin (9, 26).   719 
 The above previously described associations between higher or lower prevalence 720 
of a specific infection or variations in disease presentation as well as the association 721 
with certain autoimmune diseases are poorly understood at the functional level. They 722 
argue, however, that specific host-pathogen interactions may alter immune 723 
responsiveness in a way that impacts on the outcome of the infection. The fact that 724 
such associations have been observed even for much larger/complex organisms than 725 
JCV, e.g. M. tuberculosis, argue that the reasons must be more complex than lack of 726 
binding of peptides to the DRB1*04:01 allele. The molecular/cellular mechanisms 727 
governing a low/absent CD4+ T cell response to JCV in DRB1*04:01+ individuals 728 
together with a very strong humoral response and lack of urinary shedding, its 729 
implication for JCV immune control clearly merit further study.  730 
 Secondary to HLA DRB1*04:01, also DRB1*01+ individuals demonstrated low 731 
proliferation on JCV peptide pools, but less pronounced than in the DRB1*04:01 732 
subgroup (Fig. 4C). Additionally, PBMC from DRB1*01+ HD responded less to TTxd 733 
stimulation than other DR groups. However, these differences were not significant. 734 
Related to viral immunity, HLA-DRB1*01 has been associated with resistance to HIV 735 
infection (34), with clearance of HCV infection (16, 39, 59) and with a good 736 
responsiveness to HBsAG vaccination (10). More importantly, in analogy to HLA-DRB1-737 
04:01, HLA-DRB1*01:01 is associated with increased risk for RA (45), and these 738 
commonalities with DRB1*04:01 and other RA-associated DR alleles have been 739 
attributed to a shared motif in the peptide binding grooves of these DR molecules. 740 
Whether reduced JCV-specific T cell responses in HLA-DRB1-04:01+ and HLA-741 
DRB1*01:01+ individuals with RA contribute to the precipitation of PML, especially 742 
during immunomodulatory treatment such as rituximab (7), remains to be elucidated in 743 
larger populations. In comparison to RA patients, PML occurs even more frequently in 744 
patients with systemic lupus erythematosus (40) and natalizumab-treated MS patients 745 
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(35, 58, 61). Whether HLA associations contribute to an elevated PML risk needs to be 746 
clarified, however, in larger population-based studies.  747 
 Our assay does not allow us to distinguish directly between CD4+ T cell and 748 
CD8+ T cell driven proliferation. We have chosen 15mer peptides, which preferentially 749 
stimulate CD4+ T cell proliferation, since this length can be accommodated by the open 750 
HLA-class II binding groove in contrast to the HLA-class I binding pocket, which is 751 
closed and optimally accommodates peptides of 8-10 amino acids length. In order to 752 
use the most sensitive assay with a broad dynamic range that allows us to detect even 753 
small numbers of proliferating cells reliably we used thymidine incorporation as readout. 754 
Alternative approaches using CFSE or enzyme-linked immunosorbent spots (ELISPOT) 755 
are less sensitive, but the former can distinguish between CD4+ or CD8+ T cell 756 
proliferation. When checking the composition of the proliferating T cell population after 757 
JCV peptide- or protein stimulation by flow cytometry, we observed mainly CD4+ T cells 758 
supporting the above assumption. This does not verify exclusive CD4+ T cell 759 
proliferation, but that strong immunogenicity of some of the peptides mainly stems from 760 
CD4+ T cells with the possibility that CD8+ T cells contribute as well. By choosing an 761 
overlap of only 5 aa between adjacent peptides, we may have missed potential epitopes 762 
not covered by our selection of peptides. However, a wide range of different epitopes 763 
scattered over the entire JCV proteome may be recognized by single healthy donors as 764 
shown in Fig. 1 and 3, peptide pools from all JCV proteins were recognized (Fig. S2) 765 
and there was high inter-individual and inter-HLA-DR-group variability regarding 766 
preference and strength of reactivity against single JCV peptide pools (Fig. S3), 767 
indicating that a set of 15-mer peptides overlapping by 5 aa and covering the whole JCV 768 
proteome is sufficient to uncover the intra- and interindividual variability in epitope 769 
specificity and immunodominant JCV CD4+ T cell epitopes. 770 
 We are aware that our data give rise to a number of questions. They do, 771 
however, provide a good basis for future, more focused studies on specific aspects as 772 
well as examination of larger patient numbers, which may employ additional tools 773 
including HLA-class II tetramers loaded with JCV peptides and subsequent screening of 774 
populations of interest, like MS patients receiving natalizumab and other populations at 775 
risk for PML. In our view, assessing the T cell reactivity will, besides serological anti-776 
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JCV responses and JCV viral DNA testing, provide important additional information with 777 
respect to virus exposure of the individual and the robustness of her/his immune status. 778 
Studying the strength, antigen fine specificity and in the future also functional phenotype 779 
of the T cell response against JCV is expected to be useful as a basis for subsequent 780 
studies on JCV immune control, for diagnostic purposes and also for the development 781 
of anti JCV vaccination.  782 
 783 
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Figure Legends 1032 
 1033 
Figure 1 JCV genome organization, protein sequence variability and mapping of 1034 
peptide pools. (A) The genomic organization of the JCV reference genome 1035 
(NC_001699), consisting of 5130 bp, is shown with the nucleotide positions of all open 1036 
reading frames indicated by colored arrows. Nucleotides are numbered relative to the 1037 
JCV reference genome (NC_001699). Large T antigen (LTAg, dark blue arrow), small T 1038 
antigen (STAg, light blue arrow), three additional alternative splice variants of the large 1039 
T antigen (T’135, T’136 and T’165, dark blue arrows), agnoprotein (agno, red arrow), 1040 
VP1 (dark green arrow), VP2 (light green arrow) and VP3 (orange arrow) are shown, as 1041 
well as early and late mRNAs (grey, dotted arrows), the tandem repeats (TR, grey 1042 
boxes) in the non-coding region (NCR, grey line) and JCV miRNA (miR-J1, black dot). 1043 
Introns within the respective open reading frame are depicted as boxes with dashed 1044 
lines. (B) Sequence variability of amino acid sequences among different JCV strains 1045 
(continuous line) and among nine human PyVs (dashed line) comprised of BKV 1046 
(accession number NC_001538), JCV (NC_001699), KIV (NC_009238), WUV 1047 
(NC_009539), MCV (NC_010277), HPyV6 (NC_014406), HPyV7 (NC_014407), TSV 1048 
(NC_014361) and HPyV9 (NC_015150). Similarity scores were plotted against the 1049 
respective amino acid of each protein and matched to the relative nucleotide position of 1050 
the JCV reference genome (NC_001699). (C) Mapping of 42 peptide pools (colored 1051 
boxes) to the relative nucleotide position of the JCV reference genome (NC_001699). 1052 
LTAg, STAg, T’135, T’136 and T’165, agno, VP1, VP2 and VP3 (grey-shaded boxes) 1053 
are shown, as well as early and late mRNAs (black lines) including introns (dashed 1054 
lines) and polyadenylated 3’-ends (3’ (A)n), in relation the JCV reference genome 1055 
(NC_001699). Each pool consists of 5 different peptides. 169 peptides overlap by 5 1056 
amino acids (pep; non-hatched boxes) and 35 peptides contain single amino acid 1057 
substitutions derived from common JCV variants (var; hatched boxes). Agno is covered 1058 
by 3 peptide pools (pools 1-3, red), where pool 3 contains variants of peptides 5 (pool 1) 1059 
and 7, 9 and 12 (pool 2), all matching to agno. VP1 is covered by 13 peptide pools 1060 
(pools 4-16, dark green), where pools 12 to 16 contain variants of peptides included in 1061 
VP1 pools 4 to 11. VP2 is covered by 8 peptide pools (pools 17-24, light green), where 1062 
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pool 24 contain variants of peptides 96 (pool 20) and 106 (pool 22). VP3, the sequence 1063 
of which is identical to the N-terminal part of VP2 is covered by 6 peptide pools 1064 
(peptides 90-92 from pool 19 and pools 20-24, orange), where pool 24 contains variants 1065 
of peptides 96 (pool 20) and 106 (pool 22). LTAg is covered by 16 peptide pools (pools 1066 
25-40, dark blue) and STAg is covered by 5 peptide pools (pools 25, 26 and 40-42, light 1067 
blue), where pool 40 contains variants of peptides 185, 187 and 189 included in pool 39 1068 
(LTAg) and variants of peptides 193 and 195 includes in pool 41 (STAg). 1069 
 1070 
FIG 2 Inter-individual variability in JCV-specific immune response in healthy donors. (A, 1071 
left graphs) Proliferation of PBMC from three representative HD to 42 JCV-derived 1072 
peptide pools as measured by 3H thymidine incorporation. PBMC were stimulated with 1073 
JCV peptides assembled in 42 peptide pools (x-axis) and eight wells per pool. Pools 1074 
containing peptide variants are marked (v). Pool 3 contains variants of peptides 1075 
included in pool 1 and 2 (agno). Pools 12 to 16 contain variants of peptides included in 1076 
pools 4 to 11 (VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) 1077 
and 41 (STAg). Dots represent single stimulation indices (SI) (y-axis) and were 1078 
considered positive when SI ≥ 3 (horizontal line). (A, right graphs) Histograms 1079 
representing the mean SI of unstimulated and TTxd-stimulated wells. (B) A 1080 
representative sample shows cell proliferation by 3H thymidine incorporation (left graph; 1081 
mean SI [3H-thymidine] ± standard deviation (SD); one dot corresponds to 2 x 105 1082 
stimulated PBMC) and preferential proliferation and activation of CD4+ T cells over 1083 
CD8+ T cells after stimulation by JCV peptide pools 7 and 10 as measured by CFSE 1084 
dilution (central graph; mean SI [CFSE] ± SD; one dot corresponds to 106 stimulated 1085 
PBMC) and intracellular cytokine (IFN-γ) staining (right graph; mean SI [IFN-γ] ± SD; 1086 
one dot corresponds to 106 stimulated PBMC) in a FACS analysis. Peptide pools 7 and 1087 
10 were selected, because HD29 showed pool 7- and pool 10-reactive wells as 1088 
measured by 3H thymidine incorporation. (C) Spectrum of anti-JCV humoral responses 1089 
measured by ELISA using normalized optical density at 450nm (nOD450) in Ficoll 1090 
supernatants of cohort 1 (left graph) and sera of cohort 2 (right graph). Ficoll 1091 
supernatants were diluted by the factor 1.2 in relation to sera. (D) Urinary JC viral 1092 
shedding expressed as log10 GC/ml. 1093 
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 1094 
 1095 
FIG 3 Proliferation of PBMC to peptide pools and individual peptides. (A) 1096 
Immunogenicity of 42 pools was assessed with regard to stimulatory capacity (Sum of 1097 
SI>3) (upper graph), estimated precursor frequency (percentage of positive wells) 1098 
(middle graph) and prevalence in the tested cohort 1 (percentage of positive donors) 1099 
(lower graph). (B) Graph showing the reactivity score (RS) of the same cohort 1100 
corresponding to each pool (Σ(SI>3) x percentage of reactive wells x percentage 1101 
ofreactive individuals), which accounts for all three aspects of immunogenicity. Pools 1102 
containing peptide variants are marked (v). Pool 3 contains variants of peptides 1103 
included in pool 1 and 2 (agno). Pools 12 to 16 contain variants of peptides included in 1104 
pools 4 to 11 (VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) 1105 
and 41 (STAg). Pools 14, 17, 32, and 33 are most immunogenic in all three aspects 1106 
(blue, green, yellow, red). (C) Graphs showing the RS of cohort 2 corresponding to each 1107 
of the 20 single peptides from pools 14, 17, 32 and 33. The higher proliferations were 1108 
evoked by peptide 41 [VP1 (123-137) V3], 81 [VP2 (30-43)], 82 [VP2 (39-51)], and 162 1109 
[(LTAg (415-429)]. 1110 
 1111 
FIG 4 HLA-restricted proliferation to JCV peptide pools. (A) Frequency of DRB1 1112 
expression among 49 HD from cohort 1. (B) Proliferation measured as RS of PBMC 1113 
from DR1+, DR4+, DR7+, DR11+, DR13+, DR15+ and DR17+ HD to 42 peptide pools. 1114 
Because most donors are heterozygote with respect to DRB1* alleles, the same donor 1115 
might appear in two different HLA cohorts. For quantitative comparison of proliferation, 1116 
RS values in each HLA group were normalized to a group of 10 HD. Pools containing 1117 
peptide variants are marked (v). Pool 3 contains variants of peptides included in pool 1 1118 
and 2 (agno). Pools 12 to 16 contain variants of peptides included in pools 4 to 11 1119 
(VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) and 41 (STAg). 1120 
(C) Proliferation of PBMC from DR1+, DR4+, DR7+, DR11+, DR13+, DR15+ and DR17+ 1121 
HD measured as sum of RS from all peptide pools. (D) Proliferation measured as RS of 1122 
PBMC from DR1+, DR4+, DR7+, DR11+, DR13+, DR15+ and DR17+ HD to TTxd. Values 1123 
shown mean RS ± SEM. 1124 
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 1125 
FIG 5 HLA-restricted proliferation to individual JCV peptides. (A) Frequency of DRB1 1126 
expression among 20 HD from cohort 2. (B) Proliferation measured as RS of PBMC 1127 
from DR1+, DR7+, DR11+, DR13+, DR15+ and DR17+ HD to JCV individual peptides, 1128 
which were contained in the most immunogenic peptide pools (pools 14, 17, 32, and 1129 
33). Peptides contained in pool 14 (blue), peptides contained in pool 17 (green), 1130 
peptides contained in pool 32 (yellow) and peptides contained in pool 33 (red). For 1131 
quantitative comparison of proliferation, RS values in each HLA group were normalized 1132 
to a group of 10 HD. 1133 
 1134 
FIG 6 T cell proliferation to JCV, urinary viral shedding and JCV-specific antibody levels 1135 
in DRB1*04:01+ healthy donors. (A) Proliferation of PBMC from DRB1*04:01+ HD 1136 
(n=10) measured as RS to JCV peptide pools in comparison to PBMC from DRB1*04+ 1137 
other than DRB1*04:01+ HD (n=5). For quantitative comparison of proliferation, RS 1138 
values in each HLA group were normalized to a group of 10 HD. Pools containing 1139 
peptide variants are marked (v). Pool 3 contains variants of peptides included in pool 1 1140 
and 2 (agno). Pools 12 to 16 contain variants of peptides included in pools 4 to 11 1141 
(VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) and 41 (STAg). 1142 
(B) Proliferation of PBMC from DRB1*04:01+ and DRB1*04+ other than DRB1*04:01+ 1143 
HD measured as sum of RS from all peptide pools. (C) Proliferation measured as RS of 1144 
PBMC from DRB1*04:01+ and DRB1*04+ other than DRB1*04:01+ HD to TTxd. Values 1145 
shown mean RS ± SEM. (D) JCV urinary viral load expressed as log10 GC/ml of 1146 
DRB1*04:01+ (n=7), DRB1*04+ other than DRB1*04:01+ (n=5) and non-DR4+ HD 1147 
(n=10). (E) VLP-specific antibody levels measured by ELISA using normalized optical 1148 
density at 450nm (nOD450) in sera from DRB1*04:01+ HD (n=7), DRB1*04+ HD other 1149 
than DRB1*04:01+ (n=5) and non-DR4+ HD (n=10). (F) Antibody reactivity (mean 1150 
nOD450 ± standard error of mean) to JCV VP1 proteins after competition with soluble 1151 
BKV VP1 protein (BKV competition) or soluble JCV VP1 protein (JCV competition) in 1152 
sera of DRB1*04:01+ HD (n=5, left graph) and DRB1*04:01– HD (n=7, right graph).  1153 
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Fig 1 JCV genome organization, protein sequence variability and mapping of peptide pools.
(figure legend continued on the next page)
1
Figure 1 (figure legend continued)
(A) The genomic organization of the JCV reference genome (NC_001699), consisting of 5130 bp, is shown with 
the nucleotide positions of all open reading frames indicated by colored arrows. Nucleotides are numbered relative
to the JCV reference genome (NC_001699). Large T antigen (LTAg, dark blue arrow), small T antigen (STAg, light
blue arrow), three additional alternative splice variants of the large T antigen (T’135, T’136 and T’165, dark blue
arrows), agnoprotein (agno, red arrow), VP1 (dark green arrow), VP2 (light green arrow) and VP3 (orange arrow)
are shown, as well as early and late mRNAs (grey, dotted arrows), the tandem repeats (TR, grey boxes) in the 
non-coding region (NCR, grey line) and JCV miRNA (miR-J1, black dot). Introns within the respective open
reading frame are depicted as boxes with dashed lines. (B) Sequence variability of amino acid sequences among 
different JCV strains (continuous line) and among nine human PyVs (dashed line) comprised of BKV (accession 
number NC_001538), JCV (NC_001699), KIV (NC_009238), WUV (NC_009539), MCV (NC_010277), HPyV6
(NC_014406), HPyV7 (NC_014407), TSV (NC_014361) and HPyV9 (NC_015150). Similarity scores were plotted
against the respective amino acid of each protein and matched to the relative nucleotide position of the JCV 
reference genome (NC_001699). (C) Mapping of 42 peptide pools (colored boxes) to the relative nucleotide
position of the JCV reference genome (NC_001699). LTAg, STAg, T’135, T’136 and T’165, agno, VP1, VP2 and
VP3 (grey-shaded boxes) are shown, as well as early and late mRNAs (black lines) including introns (dashed 
lines) and polyadenylated 3’-ends (3’ (A)n), in relation the JCV reference genome (NC_001699). Each pool 
consists of 5 different peptides. 169 peptides overlap by 5 amino acids (pep; non-hatched boxes) and 35 peptides
contain single amino acid substitutions derived from common JCV variants (var; hatched boxes). Agno is covered
by 3 peptide pools (pools 1-3, red), where pool 3 contains variants of peptides 5 (pool 1) and 7, 9 and 12 (pool 2),
all matching to agno. VP1 is covered by 13 peptide pools (pools 4-16, dark green), where pools 12 to 16 contain
variants of peptides included in VP1 pools 4 to 11. VP2 is covered by 8 peptide pools (pools 17-24, light green), 
where pool 24 contain variants of peptides 96 (pool 20) and 106 (pool 22). VP3, the sequence of which is
identical to the N-terminal part of VP2 is covered by 6 peptide pools (peptides 90-92 from pool 19 and pools
(peptides 90-92 from pool 19 and pools 20-24, orange), where pool 24 contains variants of peptides 96 (pool 20) 
and 106 (pool 22). LTAg is covered by 16 peptide pools (pools 25-40, dark blue) and STAg is covered by 
5 peptide pools (pools 25, 26 and 40-42, light blue), where pool 40 contains variants of peptides 185, 187 
and 189 included in pool 39 (LTAg) and variants of peptides 193 and 195 includes in pool 41 (STAg).
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FIG 2 Inter-individual variability in JCV-specific immune response in healthy donors. (A, left graphs) Proliferation of PBMC 
from three representative HD to 42 JCV-derived peptide pools as measured by 3H-thymidine incorporation. PBMC were 
stimulated with JCV peptides assembled in 42 peptide pools (x-axis) and eight wells per pool. Pools containing peptide 
variants are marked (v). Pool 3 contains variants of peptides included in pool 1 and 2 (agno). Pools 12 to 16 contain variants 
of peptides included in pools 4 to 11 (VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) and 41 (STAg). 
'RWVUHSUHVHQWVLQJOHVWLPXODWLRQLQGLFHV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\D[LVDQGZHUHFRQVLGHUHGSRVLWLYHZKHQ6,KRUL]RQWDOOLQH$ULJKW
graphs) Histograms representing the mean SI of unstimulated and TTxd-stimulated wells. (B) A representative sample shows 
cell proliferation by 3H thymidine incorporation (left graph; mean SI [3H-thymidine] ± standard deviation (SD); one dot corres-
ponds to 2 x 105 stimulated PBMC) and preferential proliferation and activation of CD4+ T cells over CD8+ T cells after 
stimulation by JCV peptide pools 7 and 10 as measured by CFSE dilution (central graph; mean SI [CFSE] ± SD; one dot 
corresponds to 106VWLPXODWHG3%0&DQGLQWUDFHOOXODUF\WRNLQH,)1ȖVWDLQLQJULJKWJUDSKPHDQ6,>,)1Ȗ@6'RQHGRW
corresponds to 106 stimulated PBMC) in a FACS analysis. Peptide pools 7 and 10 were selected, because HD29 showed pool 
7- and pool 10-reactive wells as measured by 3H thymidine incorporation. (C) Spectrum of anti-JCV humoral responses 
PHDVXUHGE\(/,6$XVLQJQRUPDOL]HGRSWLFDOGHQVLW\DWQPQ2'450) in Ficoll supernatants of cohort 1 (left graph) and 
sera of cohort 2 (right graph). Ficoll supernatants were diluted by the factor 1.2 in relation to sera. (D) Urinary JC viral 
shedding expressed as log10 GC/ml.
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FIG 4 HLA-restricted proliferation to JCV peptide pools. (A) Frequency of DRB1 expression among 49 HD from cohort 1. 
(B) Proliferation measured as RS of PBMC from DR1+, DR4+, DR7+, DR11+, DR13+, DR15+ and DR17+ HD to 42 peptide 
pools. Because most donors are heterozygote with respect to DRB1* alleles, the same donor might appear in two different 
HLA cohorts. For quantitative comparison of proliferation, RS values in each HLA group were normalized to a group of 10 
HD. Pools containing peptide variants are marked (v). Pool 3 contains variants of peptides included in pool 1 and 2 (agno). 
Pools 12 to 16 contain variants of peptides included in pools 4 to 11 (VP1). Pool 40 contains variants of peptides included in 
pool 39 (LTAg) and 41 (STAg). (C) Proliferation of PBMC from DR1+, DR4+, DR7+, DR11+, DR13+, DR15+ and DR17+ HD 
measured as sum of RS from all peptide pools. (D) Proliferation measured as RS of PBMC from DR1+, DR4+, DR7+, DR11+, 
DR13+, DR15+ and DR17+ HD to TTxd. Values shown mean RS ± SEM.
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FIG 5 HLA-restricted proliferation to individual JCV 
peptides. (A) Frequency of DRB1 expression among 20 
HD from cohort 2. (B) Proliferation measured as RS of 
PBMC from DR1+, DR7+, DR11+, DR13+, DR15+ and 
DR17+ HD to JCV individual peptides, which were 
contained in the most immunogenic peptide pools (pools 
14, 17, 32, and 33). Peptides contained in pool 14 (blue), 
peptides contained in pool 17 (green), peptides contai-
ned in pool 32 (yellow) and peptides contained in pool 33 
(red). For quantitative comparison of proliferation, RS 
values in each HLA group were normalized to a group of 
10 HD. 
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FIG 6 T cell proliferation to JCV, urinary viral shedding and JCV-specific antibody levels in DRB1*04:01+ healthy 
donors. (A) Proliferation of PBMC from DRB1*04:01+ HD (n=10) measured as RS to JCV peptide pools in comparison to 
PBMC from DRB1*04+ other than DRB1*04:01+ HD (n=5). For quantitative comparison of proliferation, RS values in 
each HLA group were normalized to a group of 10 HD. Pools containing peptide variants are marked (v). Pool 3 contains 
variants of peptides included in pool 1 and 2 (agno). Pools 12 to 16 contain variants of peptides included in pools 4 to 11 
(VP1). Pool 40 contains variants of peptides included in pool 39 (LTAg) and 41 (STAg). (B) Proliferation of PBMC from 
DRB1*04:01+ and DRB1*04+ other than DRB1*04:01+ HD measured as sum of RS from all peptide pools. (C) Proliferati-
on measured as RS of PBMC from DRB1*04:01+ and DRB1*04+ other than DRB1*04:01+ HD to TTxd. Values shown 
mean RS ± SEM. (D) JCV urinary viral load expressed as log10 GC/ml of DRB1*04:01
+ (n=7), DRB1*04+ other than 
DRB1*04:01+ (n=5) and non-DR4+ HD (n=10).  (E) VLP-specific antibody levels measured by ELISA using normalized 
optical density at 450nm (nOD450) in sera from DRB1*04:01
+ HD (n=7), DRB1*04+ HD other than DRB1*04:01+ (n=5) and 
non-DR4+ HD (n=10). (F) Antibody reactivity (mean nOD450 ± standard error of mean) to JCV VP1 proteins after competi-
tion with soluble BKV VP1 protein (BKV competition) or soluble JCV VP1 protein (JCV competition) in sera of 
DRB1*04:01+ HD (n=5, left graph) and DRB1*04:01– HD (n=7, right graph). 
Competing VP1 concentratioQȝJPOAn
ti-
JC
V 
VP
1 
an
tib
od
y 
le
ve
l (
nO
D
45
0)
0
0.0
07
0.0
2
0.0
6
0.1
8
0.5
4
1.6
2
4.8
6
0.0
0.1
0.2
0.3
0.4
BKV competition
JCV competition
F
0
0.0
07
0.0
2
0.0
6
0.1
8
0.5
4
1.6
2
4.8
6
0.0
0.2
0.4
0.6
0.8
1.0
Competing VP1 concentratioQȝJPO
DRB1*04:01+ HD DRB1*04:01– HD
BKV competition
JCV competition
An
ti-
JC
V 
VP
1 
an
tib
od
y 
le
ve
l (
nO
D
45
0)
 1
TABLE 1 Demographic data of HD and experiments performed in the study  
 HD cohort 1 
(n=49) 
HD cohort 2 
(n=22) 
Gender (male:female) 1 : 1.33 ( 21 : 28 ) 1 : 2.14 ( 7 : 15 ) 
Mean age at date of collection, years (range) 46.5 ( 23 – 72 ) 35.4 ( 26 – 46 ) 
Caucasian, n 49 22 
HLA-typed, n 49 22 
Cellular response to peptide pools tested, n 49 0 
Cellular response to single peptides and virus-
like-particles tested, n 20 0 
Humoral response tested, n 25 22 
Urinary viral shedding tested, n 0 22 
 
 1 
TABLE 2 Immunodominant JCV peptides and their maximum sequence identity with the proteome of eight other human PyVsa 
a All protein sequences from the reference genomes of BKV (accession number NC_001538), KIV (NC_009238), WUV (NC_009539), MCV (NC_010277), 
HPyV6 (NC_014406), HPyV7 (NC_014407), TSV (NC_014361), HPyV9 (NC_015150) were used for epitope conservancy analysis (www.immuneepitope.org). 
Non-matching amino acids are grey-shaded and underlined. 
 
Immunodominant JCV epitopes Maximum 
identity 
with PyV 
proteome 
(%) 
PyV protein and 
position PyV peptide sequence 
JCV 
peptide 
no. 
JCV 
pool 
no. 
JCV protein and 
position JCV peptide sequence 
Amino 
acids 
35 14 VP1 (108-122) V3 LKTEVIGVTALMNVH 15 66.7 TSV VP1 (119-133) VKTEVVGVSSLVNVH 
41 14 VP1 (123-137) V3 SNGQASHDNGAGKPV 15 46.7 MCV VP1 (131-145) WDMKRVHDYGAGIPV 
80 17 VP2 (20-34) AATGFSVAEIAAGEA 15 100.0 BKV VP2 (20-34) AATGFSVAEIAAGEA 
81 17 VP2 (30-43) AAGEAAATIEVEIA 14 85.7 BKV VP2 (30-43) AAGEAAAAIEVQIA 
82 17 VP2 (39-51) EVEIASLATVEGI 13 92.3 BKV VP2 (39-51) EVQIASLATVEGI 
153 32 LTAg (328-342) FADSKNQKSICQQAV 15 93.3 BKV LTAg (329-343) FAESKNQKSICQQAV 
154 32 LTAg (338-351) CQQAVDTVAAKQRV 14 85.7 BKV LTAg (339-352) CQQAVDTVLAKKRV 
155 32 LTAg (347-361) AKQRVDSIHMTREEM 15 80.0 BKV LTAg (348-362) AKKRVDTLHMTREEM 
161 33 LTAg (405-419) VIYDFLKCIVLNIPK 15 73.3 BKV LTAg (406-420) VIFDFLHCIVFNVPK 
162 33 LTAg (415-429) LNIPKKRYWLFKGPI 15 80.0 BKV LTAg (416-430) FNVPKRRYWLFKGPI 

2 
Fig. S1 (figure legend continued) 
A Gating on lymphocytes, singlet cells, live cells, CD3+ cells, CD4+ and CD8+ 
cells allows for analysis of CFSEdim and IFN-Ȗ+ cells within CD4+ and CD8+ cells (HD 
29).  
B Three representative samples (HD38, HD24 and HD2 show cell proliferation 
by 3H thymidine incorporation (left graph; mean SI [3H-thymidine] ± standard 
deviation (SD); one dot corresponds to 2 x 105 stimulated PBMC) and preferential 
proliferation and activation of CD4+ T cells over CD8+ T cells as measured by CFSE 
dilution (central graph; mean SI [CFSE] ± SD; one dot corresponds to 106 stimulated 
PBMC) and intracellular cytokine (IFN-Ȗ) staining (right graph; mean SI [IFN-Ȗ] ± SD; 
one dot corresponds to 106 stimulated PBMC) in a FACS analysis after stimulation by 
JCV peptide pools identified as immunodominant in the respective donor by 3H 
thymidine incorporation. 
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Fig. S2 Frequency distribution of JCV proteins recognized by T cells from healthy donors in 
accordance with HLA-DR alleles. T cell reactivity against JCV proteins in single HD was 
assessed by measuring the T cell response against 42 JCV-derived peptide pools, which 
contain 204 JCV-encoded peptides spanning the coding regions of all JCV proteins. 
Recognized peptide pools were assigned to the respective JCV protein. The bar shows the 
frequency distribution of JCV proteins among all positive peptide pools recognized by 
T cells of all HD (n=49) and after stratification of HD into HLA-DR groups (figure legend 
continued on the next page).
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Fig. S2 (figure legend continued) 
Agnoprotein (agno, red) and its variants containing common single amino acid 
mutations (agno variants, red shaded), VP1 (dark green) and its variants containing 
common single amino acid mutations (dark green shaded), aminoterminal VP2 (N-
VP2, light green), VP3 corresponding to carboxyterminal VP2 (VP3 = C-VP2, orange) 
and its variants containing common single amino acid mutations (VP2 variants, 
orange shaded), aminoterminal small T antigen corresponding to the aminoterminal 
Large T antigen (N-STAg = N-LTAg, light blue shaded with dark blue), Large T 
antigen without aminoterminal LTAg (LTAg without N-STAg, dark blue), LTAg and 
STAg variants containing common single amino acid mutations (light blue shaded 
with black) and carboxyterminal STAg (C-STAg, light blue) are shown.  
A ratio is calculated by dividing the real frequency of positive JCV peptide 
pools per protein by the virtual frequency expected at equal reactivity to all JCV 
peptide pools and is depicted within the bars. A number higher than 1 indicates that 
peptides derived from the respective protein have been recognized more often than 
expected. A number lower than 1 indicates that peptides derived from the respective 
protein have been recognized less often than expected.!
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Figure S3 Single donor T cell reactivity against JCV proteins in HLA groups measured by 
peptide-specific responses (figure legend continued on the next page). 
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Figure S3 (figure legend continued) 
Each bar represents the T cell response against JCV-derived peptide pools in 
a single HD, and the HD were grouped according to HLA-DR groups. The bar depicts 
the number of wells showing T cell reactivity against JCV peptide pools in each HD 
after seeding of 336 wells containing 8 repeats of 42 different peptide pools, which 
comprise of 204 different JCV-encoded peptides spanning the coding regions of all 
JCV proteins.  
The recognized peptide pools are assigned to the six different JCV-encoded 
proteins. Agnoprotein (agno, red) and its variants containing common single amino 
acid mutations (agno variants, red shaded), VP1 (dark green) and its variants 
containing common single amino acid mutations (dark green shaded), aminoterminal 
VP2 (N-VP2, light green), VP3 corresponding to carboxyterminal VP2 (VP3 = C-VP2, 
orange) and its variants containing common single amino acid mutations (VP2 
variants, orange shaded), aminoterminal small T antigen corresponding to the 
aminoterminal Large T antigen (N-STAg = N-LTAg, light blue shaded with dark blue), 
Large T antigen without aminoterminal LTAg (LTAg without N-STAg, dark blue), 
LTAg and STAg variants containing common single amino acid mutations (light blue 
shaded with black) and carboxyterminal STAg (C-STAg, light blue) are shown.  
The number of positive peptide pools was corrected for background 
proliferation in each protein of each HD by calculating the (SI>3) for unstimulated 
wells (n=32), normalizing the value for the number of stimulated wells and subtracting 
it from the (SI>3) corresponding to each pool and donor. Two different thresholds 
for positivity were arbitrarily defined to identify HD with positive JCV-specific T cell 
responses, a low threshold considering that a HD has a positive JCV T cell response 
if she/he shows 3 or more wells with SI  3, and a high threshold considering 10 or 
more wells with SI  10 as a sign of positive JCV T cell response.  

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TABLE S1 HLA-DR and HLA-DQ alleles of all HD enrolled in cohort 1 
 
Donor 
number 
HLA 
serotype 
HLA alleles 
DRB1 DRB1 other DR other DR DQA1 DQA1 DQB1 DQB1 
DR DR         
HD1 11 4 1101 0401 B3*0202 B4*01XX 03XX 05XX 0301 - 
HD2 7 15 0701 1501 B4*01XX B5*0101 0102 0201 0202 0602 
HD3 13 4 1301 0401 B4*01XX B3*0202 0102 03XX 0302 0603 
HD4 15 14 1501 1404 B5*0101 B3*0202 0104 0102 0503 0602 
HD5 1 7 0101 0701 B4*01XX - 0101 0201 0202 0501 
HD6 11 - 1101 - B3*0202 - 05XX - 0301 - 
HD7 13 7 1301 0701 B4*01XX B3*0101 0103 0201 0202 0603 
HD8 11 7 1101 0701 B3*0202 B4*01XX 0201 05XX 0202 0301 
HD9 15 12 1501 1201 B3*0202 B5*0101 0102 - 0301 0602 
HD10 1 17 0101 0301 B3*0101 - 0101 05XX 0201 0501 
HD11 4 1 0401 0101 B4*01XX - 0101 03XX 0302 0501 
HD12 7 1 0701 0101 B4*01XX - 0101 0201 0202 0501 
HD13 13 4 1301 0401 B3*0101 B4*01XX 0103 03XX 0302 0603 
HD14 7 16 0701 1601 B4*01XX B5*0202 0102 0201 0202 0502 
HD15 13 15 1301 1501 B3*0101 B5*0101 0102 0103 0602 0603 
HD16 13 15 1302 1501 B3*0301 B5*0101 0102 - 0602 0604 
HD17 1 16 0101 1601 B5*0202 - 0102 0101 0501 0502 
HD18 1 17 0102 0301 B3*0202 - 05XX 0101 0201 0501 
HD19 13 17 1303 0301 B3*0101 B3*0202 05XX - 0301 0201 
HD20 13 11 1301 1101 B3*0101 B3*0202 05XX 0103 0301 0603 
HD21 4 - 0401 - B4*01XX - 03XX - 0301 0302 
HD22 13 16 1301 1601 B3*0202 B5*0202 0102 0103 0502 0603 
HD23 4 17 0401 0301 B3*0202 B4*01XX 03XX 05XX 0301 0201 
HD24 15 17 1501 0301 B3*0101 B5*0101 0102 05XX 0602 0201 
HD25 7 15 0701 1501 B4*0103N B5*0101 0102 0201 0303 0602 
HD26 17 8 0301 0801 B3*0202 - 0401 05XX 0301 0402 
HD27 11 15 1101 1501 B3*0202 B5*0101 0102 05XX 0301 0602 
HD28 13 15 1301 1501 B3*0101 - 0102 0103 0603 - 
HD29 11 7 1101 0701 B3*0202 B4*0103N 0201 05XX 0303 0301 
HD30 17 10 0301 1001 B3*0101 - 0105 05XX 0201 0501 
HD31 15 8 1501 0801 B5*0101 - 0102 0401 0602 0402 
HD32 7 12 0701 1201 B3*0202 B4*01XX 0201 05XX 0202 0301 
HD33 11 - 1101 - B3*0202 - 05XX - 0301 - 
HD34 1 7 0101 0701 B4*01XX - 0101 0201 0202 0501 
HD35 17 12 0301 1201 B3*0101 B3*0202 05XX - 0201 0301 
HD36 11 7 1101 0701 B3*0202 B4*01XX 0201 05XX 0202 0301 
HD37 13 11 1301 1101 B3*0101 B3*0202 0103 05XX 0603 0301 
HD38 13 7 1301 0701 B3*0301 B4*01XX 0102 0201 0202 0604 
HD39 15 7 1501 0701 B4*0103N B5*0101 0102 0201 0602 0303 
HD40 15 16 1501 1601 B5*0101 B5*0202 0102 - 0502 0602 
HD41 1 4 0101 0401 B4*01XX - 0101 03XX 0501 0302 
HD42 4 16 0404 1601 B4*01XX - 0102 03XX 0302 0502 
HD43 4 12 0401 1201 B3*02 B4*01 *05 *03 0301 0302 
HD44 4 17 0404 0301 - - - - 0201 0302 
HD45 4 17 0404 0301 B3*0101 B4*01 *03 *05 0201 0302 
HD46 4 16 0403 1601 B4*01 B5*0202 0102 *05 0302 0502 
HD47 4 16 0404 1601 B4*01 B5*0202 0102 *03 0302 0502 
HD48 4 13 0401 1301 B3*0202 B4*01XX 0103 03XX 0301 0603 
HD49 4 15 0401 1501 B4*01XX B5*0101 0102 03XX 0302 0602 
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TABLE S2 HLA-DR and HLA-DQ alleles of all HD enrolled in cohort 2 
 
 
HLA 
serotype 
HLA alleles 
Donor 
number 
DRB1 DRB1 other DR other DR DQA1 DQA1 DQB1 DQB1 
DR DR         
HD41 1 4 0101 0401 B4*01XX - 0101 03XX 0501 0302 
HD42 4 16 0404 1601 B4*01XX - 0102 03XX 0302 0502 
HD43 4 12 0401 1201 B3*02 B4*01 *05 *03 0301 0302 
HD46 4 16 0403 1601 B4*01 B5*0202 0102 *05 0302 0502 
HD47 4 16 0404 1601 B4*01 B5*0202 0102 *03 0302 0502 
HD48 4 13 0401 1301 B3*0202 B4*01XX 0103 03XX 0301 0603 
HD49 4 15 0401 1501 B4*01XX B5*0101 0102 03XX 0302 0602 
HD50 4 16 0402 1601 B4*01XX B5*0202 0102 03XX 0302 0502 
HD51 4 15 0404 1501 B4*01XX B5*0101 0102 03XX 0302 0502 
HD52 17 14 0301 1401 B3*0101 B3*0202 0104 05xx 0201 0503 
HD53 17 11 0301 1101 B3*0101 B3*0202 05XX - 0201 0301 
HD54 7 15 0701 1501 B4*01XX B5*0101 0102 201 0202 0602 
HD55 11 13 1101 1301 B3*0101 B3*0202 0103 05XX 0301 0603 
HD56 17 15 0301 1501 B3*0101 B5*0101 0102 05XX 0201 0602 
HD57 7 14 0701 1401 B3*0202 B4*01XX 0104 201 0202 0503 
HD58 8 11 0801 1104 B3*0202 - 0401 05XX 0301 0402 
HD59 1 9 0101 0901 B4*0103 - 0101 03XX 0303 0501 
HD60 17 14 0301 1401 B3*0101 B3*0202 0101 05XX 0201 0503 
HD61 4 15 0401 1501 B4*01XX B5*0101 0102 03XX 0302 0602 
HD62 4 16 0401 1601 B4*01XX B5*0202 0102 03XX 0302 0502 
HD63 4 13 0401 1302 B3*0301 B4*01XX 0102 03XX 0302 0609 
HD64 17 13 0301 1301 B3*0101 - 0103 05XX 0201 0603 
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TABLE S3 Frequency of HLA-DRB1 alleles in HD enrolled in cohort 1 and 2 
 
HLA serotype HLA allele 
HD observed/n in 
cohort 1 (%) 
HD observed/n in cohort 
2 (%) 
DR1  8 / 49 ( 16.3 ) 2 / 22 ( 9.1 ) 
DR4  15 / 49 ( 30.6 ) 12 / 22 ( 54.6 ) 
 DRB1*04:01 10 / 49 ( 20.4 ) 7 / 22 ( 31.8 ) 
 DRB1*04:02 0 / 49 ( 0.0 ) 1 / 22 ( 4.5 ) 
 DRB1*04:03 1 / 49 ( 2.0 ) 1 / 22 ( 4.5 ) 
 DRB1*04:04 4 / 49 ( 8.2 ) 3 / 22 ( 13.6 ) 
DR7  13 / 49 ( 26.5 ) 2 / 22 ( 9.1 ) 
DR8  2 / 49 ( 4.1 ) 1 / 22 ( 4.6 ) 
DR10  1 / 49 ( 2.0 ) 1 / 22 ( 4.6 ) 
DR11  9 / 49 ( 18.4 ) 3 / 22 ( 13.6 ) 
DR12  4 / 49 ( 8.2 ) 1 / 22 ( 4.6 ) 
DR13  12 / 49 ( 24.5 ) 4 / 22 ( 18.2 ) 
DR14  1 / 49 ( 2.0 ) 3 / 22 ( 13.6 ) 
DR15  13 / 49 ( 26.5 ) 5 / 22 ( 22.7 ) 
DR16  7 / 49 ( 14.3 ) 5 / 22 ( 22.7 ) 
DR17  10 / 49 ( 20.4 ) 5 / 22 ( 22.7 ) 
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TABLE S4 Amino acid sequence and length of JCV peptides. The position of the 
each peptide is related to the respective protein of the JCV reference genome 
NC_001699. Peptides with single amino acid mutations are designated as variants 
(V1, V2, V3).  
 
Peptide Name and position Sequence Length (aa) 
1 Agno (1-14) MVLRQLSRKASVKV 14 
2 Agno (10-25) ASVKVSKTWSGTKKR 15 
3 Agno (20-33) GTKKRAQRILIFLL 14 
4 Agno (25-39) AQRILIFLLEFLLDF 15 
5 Agno (35-49) V1 FLLDFCTGEDSVDGK 15 
6 Agno (35-49) V2 FLLDFCTGEDRVDGK 15 
7 Agno (43-57) V1 EDSVDGKKRQRHSGL 15 
8 Agno (43-57) V2 EDRVDGKKRQRHSGL 15 
9 Agno (53-65) V1 RHSGLTEQTYSAL 13 
10 Agno (53-65) V2 RHSGLTEQRYSAL 13 
11 Agno (53-65) RHSGLQEQTYSAL 13 
12 Agno (59-71) V1 EQTYSALPEPKAT 13 
13 Agno (59-71) V2 EQRYSALPEPKAT 13 
14 VP1 (1-14) V1 MAPTKRKGERKDPV 14 
15 VP1 (1-14) V2 MAPTKRKGERHDPV 14 
16 VP1 (8-22) V1 GERKDPVQVPKLLIR 15 
17 VP1 (8-22) V2 GERHDPVQVPKLLIR 15 
18 VP1 (17-31) PKLLIRGGVEVLEVK 15 
19 VP1 (26-40) EVLEVKTGVDSITEV 15 
20 VP1 (34-48) VDSITEVECFLTPEM 15 
21 VP1 (44-58) V1 LTPEMGDPDEHLRGF 15 
22 VP1 (44-58) V2 LTPEMGDPNEHLRGF 15 
23 VP1 (54-68) HLRGFSKSISISDTF 15 
24 VP1 (64-78) V1 ISDTFESDSPNRDML 15 
25 VP1 (64-78) V2 ISDTFESDSPNFDML 15 
26 VP1 (64-78) V3 ISDTFESDSPNKDML 15 
27 VP1 (74-88) V1 NRDMLPCYSVARIPL 15 
28 VP1 (74-88) V2 NFDMLPCYSVARIPL 15 
29 VP1 (74-88) V3 NKDMLPCYSVARIPL 15 
30 VP1 (81-95) YSVARIPLPNLNEDL 15 
31 VP1 (91-105) LNEDLTCGNILMWEA 15 
32 VP1 (101-115) LMWEAVTLKTEVIGV 15 
33 VP1 (108-122) V1 LKTEVIGVTSLMNVH 15 
34 VP1 (108-122) V2 LKTEVIGVTTLMNVH 15 
35 VP1 (108-122) V3 LKTEVIGVTALMNVH 15 
36 VP1 (118-129) V1 LMNVHSNGQATH 12 
37 VP1 (118-129) V2 LMNVHSNGQAAH 12 
38 VP1 (118-129) V3 LMNVHSNGQASH 12 
39 VP1 (123-137) V1 SNGQATHDNGAGKPV 15 
40 VP1 (123-137) V2 SNGQAAHDNGAGKPV 15 
41 VP1 (123-137) V3 SNGQASHDNGAGKPV 15 
42 VP1 (133-147) AGKPVQGTSFHFFSV 15 
43 VP1 (143-157) HFFSVGGEALELQGV 15 
44 VP1 (151-165) V1 ALELQGVLFNYRTKY 15 
45 VP1 (151-165) V2 ALELQGVLFNYRTTY 15 
46 VP1 (161-175) V1 YRTKYPDGTIFPKNA 15 
47 VP1 (161-175) V2 YRTTYPDGTIFPKNA 15 
48 VP1 (161-175) V3 YRTTYPHGTIFPKNA 15 
49 VP1 (171-186) FPKNATVQSQVMNTEH 16 
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50 VP1 (182-196) MNTEHKAYLDKNKAY 15 
51 VP1 (193-208) KNKAYPVECWVPDPTR 16 
52 VP1 (203-217) PDPTRNENTRYFGTL 15 
53 VP1 (210-224) NTRYFGTLTGGENVP 15 
54 VP1 (220-234) V1 GENVPPVLHITNTAT 15 
55 VP1 (220-234) V2 GENVPSVLHITNTAT 15 
56 VP1 (220-234) V3 GENVPPVLHITKTAT 15 
57 VP1 (229-243) V1 ITNTATTVLLDEFGV 15 
58 VP1 (229-243) V2 ITKTATTVLLDEFGV 15 
59 VP1 (239-253) V1 DEFGVGPLCKGDNLY 15 
60 VP1 (239-253) V2 DEFGVRPLCKGDNLY 15 
61 VP1 (249-263) GDNLYLSAVDVCGMF 15 
62 VP1 (259-273) V1 VCGMFTNRSGSQQWR 15 
63 VP1 (259-273) V2 VCGMFTKRSGSQQWR 15 
64 VP1 (259-273) V3 VCGMFTNRSGFQQWR 15 
65 VP1 (259-273) V4 VCGMFTNRAGSQQWR 15 
66 VP1 (259-273) V5 VCGMFTNGSGSQQWR 15 
67 VP1 (269-283) SQQWRGLSRYFKVQL 15 
68 VP1 (270-283) FQQWRGLSRYFKVQL 15 
69 VP1 (279-294) FKVQLRKRRVKNPYPI 16 
70 VP1 (290-304) NPYPISFLLTDLINR 15 
71 VP1 (300-314) DLINRRTPRVDGQPM 15 
72 VP1 (310-321) RVDDGQPMYGMDAQV 15 
73 VP1 (319-331) MAQVEEVRVFEGTE 14 
74 VP1 (327-341) V1 FEGTEELPGDPDMMR 15 
75 VP1 (327-341) V2 FEGTEQLPGDPDMMR 15 
76 VP1 (335-349) GDPDMMRYVDKYGQL 15 
77 VP1 (341-354) RYVDKYGQLQTKML 14 
78 VP2 (1-15) MGAALALLGDLVATV 15 
79 VP2 (11-24) LVATVSEAAAATGF 14 
80 VP2 (20-34) AATGFSVAEIAAGEA 15 
81 VP2 (30-43) AAGEAAATIEVEIA 14 
82 VP2 (39-51) EVEIASLATVEGI 13 
83 VP2 (47-61) TVEGITSTSEAIAAI 15 
84 VP2 (57-71) AIAAIGLTPETYAVI 15 
85 VP2 (67-81) TYAVITGAPGAVAGF 15 
86 VP2 (77-88) AVAGFAALVQTV 12 
87 VP2 (84-97) LVQTVTGGSAIAQL 14 
88 VP2 (93-107) AIAQLGYRFFADWDH 15 
89 VP2 (103-115) ADWDHKVSTVGLF 13 
90 VP2 (111-125) TVGLFQQPAMALQLF 15 
91 VP2 (120-134) MALQLFNPEDYYDIL 15 
92 VP2 (130-142) YYDILFPGVNAFV 13 
93 VP2 (138-152) VNAFVNNIHYLDPRH 15 
94 VP2 (148-161) LDPRHWGPSLFSTI 14 
95 VP2 (157-170) LFSTISQAFWNLVR 14 
96 VP2 (166-181) V1 WNLVRDDLPALTSQEI 16 
97 VP2 (166-181) V2 WNLVRDDLPSLTSQEI 16 
98 VP2 (177-190) TSQEIQRRTQKLFV 14 
99 VP2 (185-197) TQKLFVESLARFL 13 
100 VP2 (193-205) LARFLEETTWAIV 13 
101 VP2 (201-215) TWAIVNSPANLYNYI 15 
102 VP2 (211-225) LYNYISDYYSRLSPV 15 
103 VP2 (221-234) RLSPVRPSMVRQVA 14 
104 VP2 (230-243) VRQVAQREGTYISF 14 
105 VP2 (239-251) TYISFGHSYTQSI 13 
106 VP2 (247-260) V1 YTQSIDDADSIQEV 14 
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107 VP2 (247-260) V2 YTQSIDNADSIQEV 14 
108 VP2 (256-267) SIQEVTQRLDLK 12 
109 VP2 (263-277) RLDLKTPNVQSGEFI 15 
110 VP2 (273-286) SGEFIERSIAPGGA 14 
111 VP2 (282-296) APGGANQRSAPQWML 15 
112 VP2 (292-306) PQWMLPLLLGLYGTV 15 
113 VP2 (302-313) LYGTVTPALEAY 12 
114 VP2 (309-323) ALEAYEDGPNKKKRR 15 
115 VP2 (319-332) KKKRRKEGPRASSK 14 
116 VP2 (328-340) RASSKTSYKRRSR 13 
117 VP2 (332-344) KTSYKRRSRSSRS 13 
118 LTAg (1-14) MDKVLNREESMELM 14 
119 LTAg (10-24) SMELMDLLGLDRSAW 15 
120 LTAg (20-34) DRSAWGNIPVMRKAY 15 
121 LTAg (29-42) VMRKAYLKKCKELH 14 
122 LTAg (38-52) CKELHPDKGGDEDKM 15 
123 LTAg (48-62) DEDKMKRMNFLYKKM 15 
124 LTAg (56-70) NFLYKKMEQGVKVAH 15 
125 LTAg (63-77) EQGVKVAHQPDFGTW 15 
126 LTAg (73-85) DFGTWNSSEVPTY 13 
127 LTAg (81-94) EVPTYGTDEWESWW 14 
128 LTAg (90-105) WESWWNTFNEKWDEDL 16 
129 LTAg (99-113) EKWDEDLFCHEEMFA 15 
130 LTAg (109-123) EEMFASDDENTGSQH 15 
131 LTAg (119-133) TGSQHSTPPKKKKKV 15 
132 LTAg (129-143) KKKKVEDPKDFPVDL 15 
133 LTAg (138-152) DFPVDLHAFLSQAVF 15 
134 LTAg (148-162) SQAVFSNRTVASFAV 15 
135 LTAg (158-172) ASFAVYTTKEKAQIL 15 
136 LTAg (168-182) KAQILYKKLMEKYSV 15 
137 LTAg (176-190) LMEKYSVTFISRHGF 15 
138 LTAg (186-199) SRHGFGGHNILFFL 14 
139 LTAg (195-209) ILFFLTPHRHRVSAI 15 
140 LTAg (205-219) RVSAINNYCQKLCTF 15 
141 LTAg (215-229) KLCTFSFLICKGVNK 15 
142 LTAg (225-239) KGVNKEYLFYSALCR 15 
143 LTAg (235-249) SALCRQPYAVVEESI 15 
144 LTAg (244-258) VVEESIQGGLKEHDF 15 
145 LTAg (254-267) KEHDFNPEEPEETK 14 
146 LTAg (263-277) PEETKQVSWKLVTQY 15 
147 LTAg (273-287) LVTQYALETKCEDVF 15 
148 LTAg (282-296) KCEDVFLLMGMYLDF 15 
149 LTAg (291-305) GMYLDFQENPQQCKK 15 
150 LTAg (300-314) PQQCKKCEKKDQPNH 15 
151 LTAg (310-323) DQPNHFNHHEKHYY 14 
152 LTAg (319-332) EKHYYNAQIFADSK 14 
153 LTAg (328-342) FADSKNQKSICQQAV 15 
154 LTAg (338-351) CQQAVDTVAAKQRV 14 
155 LTAg (347-361) AKQRVDSIHMTREEM 15 
156 LTAg (357-370) TREEMLVERFNFLL 14 
157 LTAg (366-380) FNFLLDKMDLIFGAH 15 
158 LTAg (376-390) IFGAHGNAVLEQYMA 15 
159 LTAg (386-399) EQYMAGVAWIHCLL 14 
160 LTAg (395-409) IHCLLPQMDTVIYDF 15 
161 LTAg (405-419) VIYDFLKCIVLNIPK 15 
162 LTAg (415-429) LNIPKKRYWLFKGPI 15 
163 LTAg (425-439) FKGPIDSGKTTLAAA 15 
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164 LTAg (435-449) TLAAALLDLCGGKSL 15 
165 LTAg (445-458) GGKSLNVNMPLERL 14 
166 LTAg (454-466) PLERLNFELGVGI 13 
167 LTAg (462-476) LGVGIDQFMVVFEDV 15 
168 LTAg (472-486) VFEDVKGTGAESRDL 15 
169 LTAg (482-495) ESRDLPSGHGISNL 14 
170 LTAg (491-506) GISNLDCLRDYLDGSV 16 
171 LTAg (500-514) DYLDGSVKVNLERKH 15 
172 LTAg (508-522) VNLERKHQNKRTQVF 15 
173 LTAg (518-532) RTQVFPPGIVTMNEY 15 
174 LTAg (528-542) TMNEYSVPRTLQARF 15 
175 LTAg (538-552) LQARFVRQIDFRPKA 15 
176 LTAg (548-563) FRPKAYLRKSLSCSEY 16 
177 LTAg (559-574) SCSEYLLEKRILQSGM 16 
178 LTAg (570-584) LQSGMTLLLLLIWFR 15 
179 LTAg (580-594) LIWFRPVADFAAAIH 15 
180 LTAg (590-604) AAAIHERIVQWKERL 15 
181 LTAg (600-613) WKERLDLEISMYTF 14 
182 LTAg (609-622) SMYTFSTMKANVGM 14 
183 LTAg (618-631) ANVGMGRPILDFPR 14 
184 LTAg (627-642) LDFPREEDSEAEDSGH 16 
185 LTAg (638-653) V1 EDSGHGSSTESQSQCF 16 
186 LTAg (638-652) V2 EDSGHGSSTESQSQCS 16 
187 LTAg (648-662) V1 SQSQCFSQVSEASGA 15 
188 LTAg (648-662) V2 SQSQCSSQVSEASGA 15 
189 LTAg (658-672) V1 EASGADTQENCTFHI 15 
190 LTAg (658-672) V2 EASGADTQEHCTFHI 15 
191 LTAg (668-681) CTFHICKGFQCFKK 14 
192 LTAg (674-688) KGFQCFKKPKTPPPK 15 
193 STAg (73-86) DFGTWNSSEVGCDF 14 
194 STAg (73-86) DFGTWNSSEVSCDF 14 
195 STAg (82-96) V1 VGCDFPPNSDTLYCK 15 
196 STAg (82-96) V2 VSCDFPPNSDTLYCK 15 
197 STAg (92-107) TLYCKEWPNCATNPSV 16 
198 STAg (103-117) TNPSVHCPCLMCMLK 15 
199 STAg (113-127) MCMLKLRHRNRKFLR 15 
200 STAg (123-137) RKFLRSSPLVWIDCY 15 
201 STAg (133-146) WIDCYCFDCFRQWF 14 
202 STAg (142-156) FRQWFGCDLTQEALH 15 
203 STAg (149-162) DLTQEALHCWEKVL 14 
204 STAg (158-172) WEKVLGDTPYRDLKL 15 
Abbreviations: Agno = agnoprotein; LTAg = large T antigen; STAg = small T antigen; VP = viral protein. 
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TABLE S5 Distribution of the peptides among the peptide pools used for epitope 
mapping. Peptides pools contain five peptides (except of peptide pool 2) and are 
related to the respective JCV protein. Peptide pools harboring peptide variants with 
single amino acid mutations are designated as variants. 
 
 Peptides contained in the respective peptide pool  
Peptide pool Peptide 1 
Peptide 
2 
Peptide 
3 
Peptide 
4 
Peptide 
5 Protein 
1 1 2 3 4 5 Agno a 
2 7 9 12   Agno a 
3 6 8 10 11 13 Agno (variants) b 
4 14 16 18 19 20 VP1 c 
5 21 23 24 27 30 VP1 c 
6 31 32 33 36 39 VP1 c 
7 42 43 44 46 48 VP1 c 
8 49 50 51 52 53 VP1 c 
9 54 57 59 61 62 VP1 c 
10 64 67 68 69 70 VP1 c 
11 71 72 73 74 76 VP1 c 
12 15 17 22 25 28 VP1 (variants) d 
13 26 29 34 37 40 VP1 (variants) d 
14 35 38 41 45 47 VP1 (variants) d 
15 55 58 60 63 65 VP1 (variants) d 
16 66 56 75 77 192 VP1 (variants) d 
17 78 79 80 81 82 VP2 (N-VP2) e 
18 83 84 85 86 87 VP2 (N-VP2) e 
19 88 89 90 91 92 VP2 (VP2 / VP3) f 
20 93 94 95 96 98 VP2 (C-VP2 / VP3) g 
21 99 100 101 102 103 VP2 (C-VP2 / VP3) g 
22 104 105 106 108 109 VP2 (C-VP2 / VP3) g 
23 110 111 112 113 114 VP2 (C-VP2 / VP3) g 
24 115 116 117 97 107 VP2 (C-VP2 / VP3) g 
25 118 119 120 121 122 N-LTAg / N-STAg h 
26 123 124 125 126 127 N-LTAg / N-STAg h 
27 128 129 130 131 132 LTAg i 
28 133 134 135 136 137 LTAg i 
29 138 139 140 141 142 LTAg i 
30 143 144 145 146 147 LTAg i 
31 148 149 150 151 152 LTAg i 
32 153 154 155 156 157 LTAg i 
33 158 159 160 161 162 LTAg i 
34 163 164 165 166 167 LTAg i 
35 168 169 170 171 172 LTAg i 
36 173 174 175 176 177 LTAg i 
37 178 179 180 181 182 LTAg i 
38 183 184 185 186 187 LTAg i 
39 184 185 187 189 191 LTAg i 
40 186 188 190 194 196 LTAg and STAg variants j 
41 193 195 197 198 199 C-STAg k 
42 200 201 202 203 204 C-STAg k 
a Agno = peptides covering the complete agnoprotein sequence. b Agno (variants) = peptide variants harboring single amino acid 
substitutions compared to peptides of pools 1 and 2. c VP1 = peptides covering the complete agnoprotein sequence VP1 protein 
sequence. d VP1 variants = peptide variants harboring single amino acid substitutions compared to peptides of pools 4-11. e VP2 
(N-VP2) = peptides covering the aminoterminal end of VP2 protein sequence. f VP2 (VP2 / VP3) = peptides covering VP2 only 
(peptides 88-90) or both VP2 and VP3 protein sequence (peptides 91 and 92). g VP2 (C-VP2 / VP3) = peptides covering the 
carboxyterminal end of VP2 protein, the sequence of which is identical to VP3 protein. h N-LTAg / N-STAg = peptides covering 
the aminoterminal end of large T antigen, the sequence of which is identical to the aminoterminal end of small T antigen. i LTAg 
= peptides covering the large T antigen sequence. j LTAg and STAg = peptide variants (harboring single amino acid 
substitutions compared to peptides of pools 38 and 41) derived from the large T antigen sequence and from the carboxyterminal 
small T antigen sequence. k C-STAg = peptides covering the carboxyterminal end of small T antigen.  
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TABLE S6 HLA-restricted prediction scores of JCV peptides identified as immunodominant by in vitro epitope mapping in the present 
study. The consensus method from the IEDB Analysis Resource was used for calculating the HLA-restricted prediction score of the 
immunodominant JCV peptides identified in the present study. The prediction score of the consensus method displays a percentile 
rank that combines the scores of four prediction methods (ARB, combinatorial library, SMM_align and Sturniolo) after comparison with 
five million random 15-mer peptides selected from SWISSPROT database (11). A percentile rank for each of the HLA-DR alleles found 
in HD of the present study was calculated. Top percentiles scores indicate good potential binders. The consensus method was shown 
to outperform other prediction (12, 13). 
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Percentile rank calculated with IEDB Analysis Resource 
DRB1*
01:01 
DRB1*
01:02 
DRB1*
03:01 
DRB1*
04:01 
DRB1*
04:03 
DRB1*
04:04 
DRB1*
07:01 
DRB1*
08:01 
DRB1*
10:01 
DRB1*
11:01 
DRB1*
12:01 
DRB1*
13:01 
DRB1*
13:02 
DRB1*
13:03 
DRB1*
14:04 
DRB1*
15:01 
DRB1*
16:01 
35 14 VP1 (108-122) V3 29.93 4.72 9.37 10.94 13.52 5.90 7.06 6.87 26.56 8.07 27.45 14.94 31.29 37.46 33.00 17.83 39.95 
41 14 VP1 (123-137) V3 86.03 34.99 67.87 49.92 98.94 72.83 62.93 34.99 98.12 58.73 91.87 34.99 34.99 96.88 98.71 80.93 98.40 
80 17 VP2      (20-34) 30.06 16.64 40.04 13.76 20.87 16.14 29.47 5.55 23.56 11.85 65.71 15.64 54.42 63.17 58.22 45.64 54.06 
81 17 VP2     (30-43) 73.26 34.99 34.99 38.97 87.49 54.63 52.58 34.99 89.08 61.83 91.95 34.99 63.08 95.28 93.15 76.26 93.87 
82 17 VP2     (39-51) 29.75 6.46 17.88 5.06 13.75 3.07 27.84 9.35 12.94 8.05 46.67 4.62 25.37 61.61 54.46 25.08 64.09 
153 32 LTAg (328-342) 75.28 25.48 29.34 10.81 68.75 18.58 43.76 30.56 66.02 26.24 79.17 31.94 50.61 64.36 70.74 37.98 65.57 
154 32 LTAg (338-351) 58.24 21.83 30.30 31.48 72.00 26.13 28.78 31.79 68.38 26.77 58.39 28.24 49.28 73.12 75.33 57.93 71.88 
155 32 LTAg (347-361) 71.19 30.41 20.17 32.57 61.80 31.31 27.74 31.79 71.12 33.17 69.97 33.80 54.47 39.76 50.20 42.88 69.51 
161 33 LTAg (405-419) 25.51 2.93 1.71 6.04 22.10 5.48 8.01 3.58 39.26 0.38 8.57 4.25 7.76 39.64 15.28 6.89 16.16 
162 33 LTAg (415-429) 71.48 24.18 18.52 75.20 46.67 64.66 31.97 6.87 57.70 10.25 37.86 3.87 54.47 37.02 9.05 16.60 4.43 
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TABLE S7 Immunogenic BKV peptides reported in previous studies and the best matching JCV peptides used in the present study. 
Amino acids within the JCV peptides of the present study corresponding to sequences of immunogenic peptides as reported in 
previous studies are underlined. Recognition of immunogenic BKV peptides in the context of the respective HLA type is shown. 
 
Immunogenic BKV peptides (as reported in previous studies) Best matching JCV peptides (used in the present study) 
BKV protein and aa 
position BKV peptide sequence HLA binding Reference 
JCV 
peptide no. 
JCV 
pool no. 
JCV protein and aa 
position JCV peptide sequence 
BKV VP1 (44-52) AITEVECFL HLA-A*02:01 (10, 14) 20 4 JCV VP1 (34-48) VDSITEVECFLTPEM 
BKV VP1 (90-98) STARIPLPNL HLA-A*02:01 (9) 30 5 JCV VP1 (81-95) YSVARIPLPNLNEDL 
BKV VP1 (108-116) LLMWEAVTV HLA-A*02:01 (3, 14) 31 6 JCV VP1 (91-105) LNEDLTCGNILMWEA 
BKV VP1 (108-116) LLMWEAVTV HLA-A*02:01 (3) 32 6 JCV VP1 (101-115) LMWEAVTLKTEVIGV 
BKV LTAg (27-35) LPLMRKAYL HLA-B*07, HLA-
B*08 
(4) 120 25 JCV LTAg (20-34) DRSAWGNIPVMRKAY 
BKV LTAg (27-35) LPLMRKAYL HLA-B*07, HLA-
B*08 
(4) 121 25 JCV LTAg (29-42) VMRKAYLKKCKELH 
BKV LTAg (33-41) AYLRKCKEF HLA-A*24 (7) 121 25 JCV LTAg (29-42) VMRKAYLKKCKELH 
BKV LTAg (57-71) TLYKKMEQDVKVAHQ HLA-DRB1*03:01 (4) 124 26 JCV LTAg (56-70) NFLYKKMEQGVKVAH 
BKV LTAg (77-85) WSSSEVPTY HLA-A*01 (7) 126 26 JCV LTAg (73-85) DFGTWNSSEVPTY 
BKV LTAg (156-164) RTLACFAVY HLA-A*03 (7) 134 28 JCV LTAg (148-162) SQAVFSNRTVASFAV 
BKV LTAg (157-165) TLACFAVYT HLA-A*02:01 (5) 134 28 JCV LTAg (148-162) SQAVFSNRTVASFAV 
BKV LTAg (157-165) TLACFAVYT HLA-A*02:01 (5) 135 28 JCV LTAg (158-172) ASFAVYTTKEKAQIL 
BKV LTAg (159-167) ACFAVYTTK HLA-A*03 (7) 135 28 JCV LTAg (158-172) ASFAVYTTKEKAQIL 
BKV LTAg (172-180) ILYKKLMEK HLA-A*03 (7) 136 28 JCV LTAg (168-182) KAQILYKKLMEKYSV 
BKV LTAg (208-216) SAINNFCQK HLA-A*03 (7) 140 29 JCV LTAg (205-219) RVSAINNYCQKLCTF 
BKV LTAg (216-224) KLCTFSFLI HLA-A*02:01 (5) 141 29 JCV LTAg (215-219) KLCTFSFLICKGVNK 
BKV LTAg (222-230) FLICKGVNK HLA-A*03 (7) 141 29 JCV LTAg (215-219) KLCTFSFLICKGVNK 
BKV LTAg (227-235) GVNKEYLLY HLA-A*03 (7) 142 29 JCV LTAg (225-239) KGVNKEYLFYSALCR 
BKV LTAg (235-243) YSALTRDPY HLA-A*01 (7) 143 30 JCV LTAg (235-249) SALCRQPYAVVEESI 
BKV LTAg (242-250) PYHTIEESI HLA-A*24 (7) 143 30 JCV LTAg (235-249) SALCRQPYAVVEESI 
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BKV LTAg (270-278) VSWKLITEY HLA-A*01 (7) 146 30 JCV LTAg (263-277) PEETKQVSWKLVTQY 
BKV LTAg (287-295) VFLLLGMYL HLA-A*24 (7) 148 31 JCV LTAg (282-296) KCEDVFLLMGMYLDF 
BKV LTAg (313-327) PYHFKYHEKHFANAI HLA-DRB1*01:01, HLA-DRB1*07:01 (6) 151 31 JCV LTAg (310-323) DQPNHFNHHEKHYY 
BKV LTAg (362-371) MLTERFNHIL HLA-A*02:01 (8, 14) 156 32 JCV LTAg (357-370) TREEMLVERFNFLL 
BKV LTAg (388-396) QYMAGVAWL HLA-A*24 (7) 159 33 JCV LTAg (386-399) EQYMAGVAWIHCLL 
BKV LTAg (394-402) AWLHCLLPK HLA-A*03 (7) 159 33 JCV LTAg (386-399) EQYMAGVAWIHCLL 
BKV LTAg (394-402) AWLHCLLPK HLA-A*03 (7) 159 33 JCV LTAg (386-399) IHCLLPQMDTVIYDF 
BKV LTAg (398-406) CLLPKMDSV HLA-A*02:01 (1) 160 33 JCV LTAg (395-409) IHCLLPQMDTVIYDF 
BKV LTAg (406-414) VIFDFLHCI HLA-A*02:01 (5, 8, 14) 161 33 JCV LTAg (405-419) VIYDFLKCIVLNIPK 
BKV LTAg (410-408) FLHCIVFNV HLA-A*02:01 (5, 8) 161 33 JCV LTAg (405-419) VIYDFLKCIVLNIPK 
BKV LTAg (414-422) IVFNVPKRR HLA-A*03 (7) 161 33 JCV LTAg (405-419) VIYDFLKCIVLNIPK 
BKV LTAg (414-422) IVFNVPKRR HLA-A*03 (7) 162 33 JCV LTAg (415-429) LNIPKKRYWLFKGPI 
BKV LTAg (422-430) RYWLFKGPI HLA-A*24 (7) 162 33 JCV LTAg (415-429) LNIPKKRYWLFKGPI 
BKV LTAg (472-480) VVFEDVKGT HLA-A*02:01 (10) 168 35 JCV LTAg (472-486) VFEDVKGTGAESRDL 
BKV LTAg (506-514) SVKVNLEKK HLA-A*03 (9) 171 35 JCV LTAg (500-514) DYLDGSVKVNLERKH 
BKV LTAg (553-567) IYLRKSLQNSEFLLE HLA-A*02:01 (8) 176 36 JCV LTAg (548-563) FRPKAYLRKSLSCSEY 
BKV LTAg (557-571) KSLQNSEFLLEKRIL HLA-A*02:01 (8) 177 36 JCV LTAg (559-574) SCSEYLLEKRILQSGM 
BKV LTAg (558-566) SLQNSEFLL HLA-A*02:01 (5) 176 36 JCV LTAg (548-563) FRPKAYLRKSLSCSEY 
BKV LTAg (558-566) SLQNSEFLL HLA-A*02:01 (5) 177 36 JCV LTAg (559-574) SCSEYLLEKRILQSGM 
BKV LTAg (579-587) LLLIWFRPV HLA-A*02:01 (5, 8, 14) 178 37 JCV LTAg (570-584) LQSGMTLLLLLIWFR 
BKV LTAg (579-587) LLLIWFRPV HLA-A*02:01 (5, 8) 179 37 JCV LTAg (580-594) LIWFRPVADFAAAIH 
BKV LTAg (604-612) RLDSEISMY HLA-A*01 (7) 181 37 JCV LTAg (600-613) WKERLDLEISMYTF 
BKV LTAg (613-627) TFSRMKYNICMGKCI HLA-A*02:01, HLA-DRB1*09:01 (4) 182 37 JCV LTAg (609-622) SMYTFSTMKANVGM 
BKV LTAg (613-627) TFSRMKYNICMGKCI HLA-A*02:01, HLA-DRB1*09:01 (4) 183 38 JCV LTAg (618-631) ANVGMGRPILDFPR 
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TABLE S8 BKV- and JCV-crossreactive peptides reported in previous studies and compared to the best matching JCV peptides used 
in the present study. Amino acids, which are contained within the JCV peptides used in the present study and which show the 
sequence of the crossreactive JCV peptide, are underlined. Crossreactive peptide sequences are shown in the context of the 
respective HLA type. 
 
BKV-encoded peptides crossreactive to JCV (reported in previous studies) Best matching JCV peptides (used in the present study) 
BKV protein and aa 
position BKV peptide sequence HLA binding Reference 
JCV 
peptide no. 
JCV 
pool no. 
JCV protein and aa 
position JCV peptide sequence 
BKV VP1 (44-52) AITEVECFL HLA-A*02:01 (2, 10) 20 4 JCV VP1 (34-48) VDSITEVECFLTPEM 
BKV VP1 (108-116) LLMWEAVTV HLA-A*02:01 (3) 31 6 JCV VP1 (91-105) LNEDLTCGNILMWEA 
BKV VP1 (108-116) LLMWEAVTV HLA-A*02:01 (3) 32 6 JCV VP1 (101-115) LMWEAVTLKTEVIGV 
BKV LTAg (27-35) LPLMRKAYL HLA-B*07, HLA-B*08 (4) 120 25 JCV LTAg (20-34) DRSAWGNIPVMRKAY 
BKV LTAg (27-35) LPLMRKAYL HLA-B*07, HLA-B*08 (4) 121 25 JCV LTAg (29-42) VMRKAYLKKCKELH 
BKV LTAg (553-567) IYLRKSLQNSEFLLE HLA-A*02:01 (4) 176 36 JCV LTAg (548-563) FRPKAYLRKSLSCSEY 
BKV LTAg (557-571) KSLQNSEFLLEKRIL HLA-A*02:01 (4) 177 36 JCV LTAg (559-574) SCSEYLLEKRILQSGM 
BKV LTAg (613-627) TFSRMKYNICMGKCI HLA-A*02:01, HLA-DRB1*09:01 (4) 182 37 JCV LTAg (609-622) SMYTFSTMKANVGM 
BKV LTAg (613-627) TFSRMKYNICMGKCI HLA-A*02:01, HLA-DRB1*09:01 (4) 183 38 JCV LTAg (618-631) ANVGMGRPILDFPR 
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